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p73, the structural and functional homologue of p53, exists as two major forms: the pro-
apoptotic TAp73 or the anti-apoptotic DNp73. Unlike p53, p73 is rarely mutated in 
cancers. However, both TAp73 and DNp73 are often up-regulated in many tumors. Upon 
genotoxic stresses such as chemotherapeutic drugs, TAp73 is stabilized mainly through 
post-translational modifications, leading to its pro-apoptotic activities and concomitantly, 
DNp73 is degraded through poorly understood mechanisms. Presence of dominant-
negative oncogenic DNp73 is often associated with chemoresistance in many cancers. 
Expectedly, a balance in the expression of both these major forms has to be coordinated 
precisely to achieve the desired cellular outcome.  
In the first part of this study, we have therefore investigated the possible mechanisms of 
stress-induced DNp73 degradation and show here that c-Jun, the AP-1 family member 
activated by stress signals and involved in stabilizing TAp73, promotes DNp73 
degradation. Genotoxic stress-mediated DNp73 degradation was found to occur in a c-
Jun-dependent manner through an ubiquitin-independent but proteasome-dependent 
mechanism. Absence or down-regulation of c-Jun expression abrogated reduction of 
DNp73 levels upon stress insults whereas over-expression of c-Jun led to its degradation. 
c-Jun controlled DNp73 degradation through the non-classical, polyamine-induced 
antizyme (Az) pathway, by regulating the latter’s processing during stress response. 
Consistently, expression of c-Jun or Az1, or addition of polyamines promoted DNp73 
degradation, whereas silencing Az1 expression or inhibiting Az1 activity in cells exposed 
to stress reduced c-Jun-dependent DNp73 degradation. Moreover Az1 was able to bind to 
DNp73. These data together demonstrate the existence of a novel c-Jun-dependent 
 xiv
mechanism regulating the abundance of the anti-apoptotic DNp73 in response to 
genotoxic stress. 
Non-genotoxic stresses such as hypoxia play an important role in supporting 
tumorigenesis. Several studies have recently shown that TAp73 and DNp73 have also the 
ability to promote cell growth and survival. Here we show that hypoxia induces the 
stabilization of both TAp73 and DNp73. This process did not require VHL E3 ubiquitin 
ligase, a key regulator known to modulate hypoxia-regulated proteins but involved a 
prolyl-4-hydroxylase enzyme. Additionally, we found that AMPK signaling pathway was 
required for p73 stabilization under low oxygen tension and this was abrogated in the 
absence of the two catalytic subunits, AMPKα1 and AMPKα2. Lastly, autophagy, a 
downstream effect of hypoxia, regulated partly by AMPK, was reduced in the absence of 
p73. 
Overall, we have demonstrated the mechanism via which oncogenic DNp73 is degraded 
upon genotoxic stresses. We have also found a possible novel function of p73 in 
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Chapter 1: Introduction 
 
1.1 p73, a member of the p53 family of tumor suppressors 
The p53 family of transcription factors consists of p53, p63 and p73. p53, the most well-
studied tumor suppressor gene, was the first member of this family to be discovered 30 
years ago. Subsequently two genes highly homologous to p53 were cloned and named 
p63 and p73 (Kaghad M et al., 1997; Yang A et al., 1998).  All the family members share 
striking similarity within the sequences of their amino (N-)-terminal transactivation 
domain, the central DNA-binding domain and the carboxyl (C-)-terminal oligomerization 
domain (Illustration 1.1). Having highly conserved domains, all three proteins can 
regulate the transcription of an overlapping subset of genes that usually contain p53-
responsive elements (DeYong MP and Ellisen LW, 2007). The p53 family members have 
been shown to suppress tumor formation by several mechanisms namely induction of 
apoptosis or cell cycle arrest (Melino G et al., 2002). However, each member can also 
transactivate unique set of genes, indicating that despite their structural similarities, all 
members also have distinct roles in regulating cellular outcome (Melino G et al., 2002). 
 
1.2 Forms of p73  
Similar to the other members of the family, p73 is expressed in multiple forms because of 
the presence of two promoters and alternative splicing at the C-terminal (DeYong MP 
and Ellisen LW, 2007, Marabese M et al., 2007) (Illustration 1.1). The full-length version 
of p73, called TAp73 from here onwards, is transcribed from the P1 promoter. The 
transcript arising from promoter P2 codes for the N-terminal truncated version of p73 
called DNp73 from here onwards. Both are considered as the major forms of p73 and 
each one can give rise to a subset of isoforms (p73α-η) due to alternative splicing (De 
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Laurenzi V et al., 1998).  TAp73α being the longest form contains two additional 
domains known as the sterile alpha motif (SAM) and the transactivation inhibitory 
domain (TID) at the C-terminal (Ueda Y et al., 1999). A recent study has shown that p73 
expression can be regulated by an additional mechanism using a putative internal 
ribosome entry site (IRES) located in exon 2 (Sayan AE et al., 2007). The alternative 
translation initiation site of TAp73 mRNA can generate a DNp73-like peptide, 
illustrating that a DNp73 protein can be produced from a transcript originally generated 
from the P1 promoter. To date, the distinct functional contributions of all these forms of 

























Illustration 1.1 Structure and expression of p53 family members. (A) Structure of p53, p63 and p73 
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1.3 Knock-out models of p73 
Several mouse models have been generated for all members of the p53 family. 
Homozygous deletion of p53 gene in mice leads to the formation spontaneous tumors 
(Donehower LA et al., 1992). p63 null mice die at birth because of severe developmental 
defects mainly due to abnormal epidermis (Mills AA et al., 1999). The first knock-out 
model generated for p73 (p73-/-), where both TAp73 and DNp73 were deleted, are viable 
but the pups have a runted appearance and die within a few weeks post-natally (Yang A 
et al., 2000). These mice also have other defects such as mild congenital hydrocephalus, 
hippocampal dysgenesis, abnormal sensory pathways, chronic infection and 
inflammation. Interestingly, both p63 and p73 heterozygous mice do develop 
spontaneaous tumors (Flores ER et al., 2005), indicating that they might function as 
tumor suppressors but in a different manner to p53. Mechanisms underlying the various 
phenotypes of the p73 null mice have been difficult to interpret due to the distinct 
functions of TAp73 and DNp73. However, recently, both TAp73-specific (TAp73-/-) and 
DNp73-specific (DNp73-/-) knock-out mice model were generated. TAp73-/- mice 
showed less severe developmental defects but an increase incidence of spontaneous 
tumors, hence providing strong evidence that TAp73 is indeed a tumor suppressor 
(Tomasini R et al., 2008). On the other hand, DNp73-/- mice displayed signs of 
neurodegeneration. DNp73-/- MEFs were also sensitized to genotoxic stresses and had 
increase p53-dependent apoptosis, indicating that DNp73 is important in 
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1.4 p73 and cancer 
Unlike p53, which is mutated in >50% of human cancers, extensive mutational analyses 
have shown that p73 is rarely mutated (<1%) (Melino G et al., 2002). The surprising 
observations from subsequently studies showed that p73 mRNA and/or protein is 
frequently over-expressed in many different types of tumors such as lung, neuroblastoma, 
colon, ovarian and liver and many others (Zaika AI et al., 2002; Uramoto H et al., 2004; 
Dominguez G et al., 2006). Recently, a large cohort of ovarian tumors was shown to have 
both TAp73 and DNp73 mRNA co-upregulated (Concin N et al., 2005). Similarly, both 
TAp73 and DNp73 protein have been observed to be co-upregulated in primary 
rhabdomyosarcomas (Cam H et al., 2006). Over-expression of only DNp73 mRNA has 
been associated with poor prognosis in low-grade gliomas and advanced breast and colon 
carcinomas (Wager M et al., 2006). Interestingly, both TAp73 and DNp73 levels were 
up-regulated in cervical squamous cell carcinoma in a mutually exclusive manner and 
high levels of DNp73 correlated with resistance to irradiation and disease recurrence (Liu 
SS et al., 2006). However the reason for over-expression of TAp73 or DNp73 is not 
clear. All of the above indicate a balance between TAp73 and the dominant negative 
DNp73 expression might be an important factor in tumorigenesis. 
 
1.5 p73 and chemotherapeutic response 
TAp73 is activated by a multitude of chemotherapeutic agents such as camptothecin, 
cisplatin, doxorubicin, taxol and nocodazol (Lin KW et al., 2004), linking its function to 
the chemosensitivity of cancer cells. However, several mechanisms inhibiting TAp73 
pro-apoptotic activity in response to chemotherapeutic drugs, often lead to poor clinical 
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outcome. Mutant p53 has been shown to bind and inactivate TAp73 depending on the 
type of p53 mutation and the polymorphism at codon72 of p53 gene (Tada M et al., 
2001). It is noteworthy that wild-type p53 does not bind to TAp73 and only certain DNA-
binding domain mutants of p53, is able to bind to TAp73 due to a conformational change 
in p53 protein via its core domain and that of DNA-binding domain and/or 
oligomerization domain of p73 (Strano S et al., 2000). A large study of ovarian cancer 
patients showed that individuals carrying p53 mutants known to inhibit TAp73 function, 
correlated with poor overall survival of the patients (Concin N et al., 2004). Similarly, 
p53 codon72 polymorphism in combination with mutations has a negative effect on 
TAp73-dependent apoptosis upon chemotherapeutic treatment in head and neck cancer 
patients with Arg cells being more chemoresistant (Bergamaschi D et al., 2003). The 
over-expression of dominant-negative DNp73 in many cancers would suggest that it is 
capable of inhibiting drug-induced apoptosis in cancers that retain wild-type p53 and/or 
TAp73, hence leading to chemoresistance (Slade N et al., 2004). However, the role of 
DNp73 in chemoresistance was further complicated when recent studies have shown that 
DNp73β could in fact induce apoptosis and cell cycle arrest (Liu G et al., 2004). 
Furthermore, over-expression of DNp73α did not affect the chemosensitivity of HCT116 
cells treated with cisplatin and doxorubicin (Marabese M et al., 2005). However, most 
studies show that the predominant role of DNp73 is still anti-apoptotic, hence more 
investigations into the complex mechanisms regulating the expression of p73 in cancers 
are needed to better understand the outcome of chemotherapeutic treatment. 
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1.6 p73 and genotoxic stress 
p73 regulation has been well studied in response to genotoxic insults. These stresses often 
dictate p73 response by inducing post-translational modifications such as 
phosphorylation by c-Abl kinase on both TAp73 and DNp73 leading to their stabilization 
(Agami R et al., 1999; Yuan ZM et al., 1999; Gong JG et al., 1999) or via the recruitment 
of other factors such as Itch E3 ubiquitin ligase, which selectively regulate TAp73 and 
not DNp73 under stress conditions (Rossi M et al., 2005). TAp73 and DNp73 can 
respond differently depending on the type of genotoxic stresses used and the signaling 
pathways that are triggered. The ideal scenario is an up-regulation of pro-apoptotic 
TAp73 and the concomitant degradation of oncogenic DNp73 upon DNA-damaging 
insults, which will ensure that proper cellular response, is achieved. The different ways 
by which the level of TAp73 and DNp73 are regulated by genotoxic stresses will be 
discussed further in sections 1.11-1.13.  
 
1.7 p73 and non-genotoxic stress 
Non-genotoxic stresses such as heat shock, osmotic shock, serum starvation and hypoxia 
are stimuli that do not directly cause damage to the DNA. However, there are increasing 
evidence suggesting that this type of stress do have an impact on tumor onset, 
development and progression. For example, genetic instability, one of the hallmarks of 
cancer (Hanahan D and Weinberg RA, 2000), can be induced by non-genotoxic stress 
exposures such as heat treatment, serum starvation and hypoxia, similar to genotoxic 
stresses like ionizing radiation (Li CY et al., 2001). Heat shock and hypoxia induce stress 
response mainly by denaturing proteins and inhibiting oxygen-dependent metabolism 
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respectively. p53, arguably the most important regulators of cellular integrity, has been 
shown to be up-regulated by many of these non-genotoxic stresses (Pluquet O and 
Hainaut P, 2001). The increase in nuclear p53 protein levels and DNA-binding activity 
following hypoxia occur in cells that express wild type for p53 but not in cells that having 
mutant p53, suggesting that hypoxia is an example of a non-genotoxic stress which 
induces p53 activity by a different pathway than DNA-damaging agents (Graeber TG et 
al., 1994). On the other hand, not much is known about p73 regulation by non-genotoxic 
stresses. A recent study has shown that p73 is up-regulated by serum starvation, leading 
to the induction PUMA to trigger apoptosis in human cancer cells, independent of p53 
(Ming L et al., 2008). Therefore, it is clear that exploring the effect of non-genotoxic 
stresses such as hypoxia on p73 levels and their physiological outcome, is crucial to get a 
better understanding of the intricate processes of tumorigenesis. 
 
1.7.1 Hypoxia 
Cells require molecular oxygen (O2) to function properly and for the activation of many 
biochemical reactions. Hypoxia is defined as reduced O2 levels and has been shown to 
occur in a variety of pathological conditions, including stroke, inflammation and growth 
of solid tumors  (Denko NC, 2008). Even though ambient air is of 21% O2 (normoxia), 
most mammalian tissues exist at 2%–9% O2 in the body. Hypoxia is usually defined as 
≤2% O2 and severe hypoxia (or anoxia) is defined as ≤0.02% O2. Hypoxia has been 
associated with increased resistance to radiotherapy and poor prognosis in solid tumors 
(Semenza GL, 2003; Evans SM and Koch CJ, 2003) and majority of solid tumors contain 
poorly oxygenated regions (Brown JM and Wilson WR, 2004). One of the main effectors 
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in response to hypoxia is hypoxia-inducible factors (HIFs) (Weidemann A and Johnson 
RS, 2008). HIF-1, a heterodimeric transcription factor, is composed of HIF-1α and HIF-
1β subunit, which is primarily responsible to regulate the expression of numerous genes 
associated with hypoxic responses such as angiogenesis, metabolism, proliferation and 
autophagy (Weidemann A and Johnson RS, 2008). 
 
1.7.2 Regulation of HIF1α 
HIF1α regulation is primarily based on post-translational modification and protein 
stability. Under normoxic conditions, HIF-1α is subjected to ubiquitination and rapid 
proteasomal degradation via the binding of the von Hippel-Lindau (VHL) tumor 
suppressor protein (Kaelin WG, 2008). VHL is the substrate recognition component of a 
ubiquitin protein ligase complex that includes Elongin B, Elongin C, Cullin2 and Ring 
box protein 1 (RBX1), forming part of the Skp/Cullin/F-box (SCF) family of ubiquitin 
ligases (Illustration 1.2) (Pavlovich CP and Schmidt, 2004). Under normoxic conditions, 
VHL binds to HIF-1α that is hydroxylated on proline residue 402 and/or 564 by prolyl-4-
hydroxylases (PHDs), leading to its ubiquitination and subsequent proteasomal 
degradation (Schofield CJ and Ratcliffe PJ, 2004). Additionally, asparagine residue 803 
is also hydroxylated by factor inhibiting HIF-1 (FIH-1) that prevents the binding of the 
co-activators CBP and p300 to HIF-1α, hence inhibiting its transcriptional activity 
(Mahon PC et al., 2001). However, under hypoxic conditions, hydroxylation, 
ubiquitination and degradation of HIF1α are inhibited, leading to its accumulation and 
subsequent transactivation of its target genes. 
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Illustration 1.2 Schematic showing regulation of HIF1α by VHL E3 ligase. (Adapted from Pavlovich 
C.P and Schmidt S.L., 2004) 
 
These hydroxylases have distinct affinity for O2 with FIH having a higher affinity for O2 
than PHDs, therefore allowing activation of different sets of genes according to the 
degree of hypoxia, thereby fine-tuning the desired responses (Kaelin WG and Ratcliffe 
PJ, 2008). 
 
1.7.3 Hypoxia regulated pathways 
Hypoxia-inducible genes are involved in several biological processes, including cell 
proliferation, angiogenesis, apoptosis and metabolism (Carmeliet P et al., 1998). The 
pathways that are induced depend on the amount of O2 and the duration of the hypoxic 
stress. Upon initial exposure to low O2, cells will trigger survival mechanisms in order to 
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adapt to the new physiological conditions (Semenza GL, 2003). For example, in response 
to hypoxia, HIF-1α up-regulates the expression of various growth factors such as 
vascular endothelial growth factor (VEGF), a key angiogenic protein that is secreted by 
both normal and cancer cells to promote cell proliferation by increasing the O2 delivery 
(Pouyssegur J et al., 2006). Moreover, low O2 exposure induces cells to shift to 
glycolysis, an O2–independent pathway for glucose metabolism in order to generate 
enough ATP to maintain cell viability (Denko NC, 2008). HIF-1α has also been shown to 
regulate expression of several glycolytic enzymes such as the glucose transporters 
GLUT1 and GLUT3 to increase the flux from glucose to lactate (Iyer NV et al., 1998).  
When not enough ATP is generated to sustain survival, cells trigger the autophagic 
pathway via the induction of the atypical BH3-only protein the Bcl-2 adenovirus E1a 
19kDa-interacting protein 3 (BNIP3) (Zhang H et al., 2008). This process causes the 
digestion of macromolecules and organelles in the cells in order to obtain an alternative 
energy source. Hypoxia has also been shown to trigger the unfolded protein response 
(UPR) pathway as a method for cells to adapt to increase ER stress and hence better 
survival chances (Feldman DE et al., 2005; Wouters BG and Koritzinsky M, 2008). 
However, upon chronic hypoxia or anoxia (<1% O2), cells that fail to adapt, undergo 
HIF1α-dependent and -independent autophagic cell death via pathways (Mazure NM and 
Pouyssegur J, 2009). It is important to note that although the HIFs are crucial mediators 
of the transcriptional response to hypoxia, a number of HIF-independent pathways also 
respond to changes in O2 tension. Therefore understanding how these pathways perceive 
and react to different hypoxic conditions and what other regulators of hypoxic response 
exist, is vital. 
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1.7.3 Hypoxia and p53 family 
Effect of hypoxia has so far only been studied in respect to p53. Currently, there are no 
data showing the regulation of p63 and p73 by hypoxic stress. Hypoxia leads to the 
stabilization of p53 protein (An WG et al., 1998). This has been attributed to the binding 
of HIF1α to p53 protein, but however the exact mechanism of this relationship and how 
it leads to p53 accumulation is still unknown (Hammond EM and Giaccia AJ, 2006). The 
interpretation has been further complicated when a recent study claimed that p53 
stabilization upon hypoxia is not due to the low oxygen environment per se, but because 
of acidosis and nutrient deprivation in the tumor microenvironment (Pan Y et al., 2004). 
The major role of p53 is to mediate apoptosis in response to hypoxia. Tumors with 
functional p53 undergo significant hypoxia-mediated cell death compared to p53 null 
tumors (Graeber TG et al., 1994), hence acting as a selection pressure for cells with a low 
apoptotic potential. Further studies have indicated that p53-dependent cell death upon 
hypoxia occurs via several pathways. Apoptosis can occur via the release of cytochrome 
c from the mitochondria and subsequent activation of Apaf-1 and caspase-9 activity 
(Soengas MS et al., 1999). p53 has also been reported to induce cell death upon hypoxia 
via PUMA, similar to its response upon DNA damaging agents (Yu J et al., 2003). 
Additionally, hypoxia-induced cell death has been shown to be dependent via p53 
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1.8 p73 and cell death 
Similar to p53, ectopic expression or the activation of TAp73 by chemotherapeutic drugs 
can trigger apoptosis through different mechanisms (Jost CA et al., 1997; Ramadan S et 
al., 2005). It is noteworthy that TAp73α is less effective in transactivation and apoptosis 
induction compared to TAp73β due to the TID domain found only at the C-terminal of 
TAp73α (Serber Z et al., 2002).  It is believed that p73 induces apoptosis by several 
distinct mechanisms. For example, TAp73 induces ER stress via the direct transactivation 
of Scotin, an ER-associated protein, which lead to apoptosis via alteration in the 
intracellular concentration of free calcium and caspases activation (Terrinoni A et al., 
2004). Additionally, CHOP/Gadd153, a transcription factor often induced in ER stress 
situation, has been shown as a target of TAp73α (Terrinoni A et al., 2004). TAp73 can 
also induce the mitochondrial pathway by directly transactivating both Bax and the BH3-
only protein PUMA promoters (Melino G et al., 2004). PUMA induction enhances Bax 
conformational change and its translocation to the mitochondria where it triggers the 
release of cytochrome C and subsequent activation of downstream caspases. Furthermore, 
TAp73 is also able to activate the death receptor pathway via the transactivation of death 
receptor CD95 (Schilling T et al., 2009). Recently, activation of Bim, another member of 
the BH3-only family of protein by p73 has been involved in mitotic cell death (Toh WH 
et al., 2009). Bim was shown as a direct target of p73 and absence of p73 inhibited 
mitotic death via reduction in Bim levels and thereby affecting the release of cytochrome 
c and activation of caspases. 
Conversely, DNp73 is known to exert a dominant-negative effect on both TAp73 and p53 
(Grob TJ et al., 2001). DNp73, which still retains the DNA-binding and oligomerization 
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domains can inhibit the activity of these two tumor suppressors by oligomerization to 
form heteromeric complexes or by competing for binding at the promoter of target genes 
(Stiewe T et al., 2002; Nakagawara T et al., 2002; Zaika AI et al., 2002), hence blocking 
theirs transactivation ability and potential to induce apoptosis.  
Indeed, DNp73 expression has been demonstrated to suppress E1A or c-Myc induced 
apoptosis in primary fibroblasts partially via its transdominant effect of p53 and 
potentially TAp73 (Petrenko O et al., 2003).  In addition, many p53 mutants have also 
been shown to suppress TAp73 apoptotic functions after DNA-damage response 
(Bergamaschi D et al., 2003). Interestingly, recent studies have shown that DNp73 
isoforms, generally believed to be transcriptionally inactive due to the absence of the 
transactivation domain, can induce transcription of some genes, albeit to a lesser extent 
than TAp73 isoforms. In SAOS2 cell line, DNp73β and not DNp73α expression 
increased the level of Mdm2 and p21 leading to cell cycle arrest or apoptosis (Liu G et 
al., 2004). Additionally, DNp73α has been shown to bind to the promoter of tumor 
suppressor PTEN and transcriptionally reduce its expression in thyroid cells, leading to 
increase proliferation and reduce apoptosis (Vella V et al., 2009). Moreover, DNp73α 
was able to activate heat shock factor (HSF)-responsive gene such as Hsp70 (Tanaka Y et 
al., 2004) and platelet-derived growth factor beta-receptor (PDGFRB)  (Wetterskog D et 
al., 2009), indicating that DNp73 forms can have some distinct transcriptional activity 
depending on the cellular context. This was further emphasized with a recent report 
showing that p73 has a potential second transactivation domain at the C-terminal end of 
p73 within amino acid residues 381 to 399, common in both TAp73 and DNp73 (Nyman 
U et al., 2009). The C-terminal transactivation domain was found to preferentially 
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regulate genes involved in cell cycle progression compared to N-terminal transactivation 
domain, which is crucial for p73 pro-apoptotic functions. 
 
1.9 p73 and cell survival/proliferation 
As previously described, both TAp73 and DNp73 are often found to be up-regulated in 
cancers. While the over-expression of DNp73 in cancers has been shown to function in a 
dominant negative manner inhibiting the apoptotic functions of p53 and TAp73, the 
reason for high level of the ‘pro-apoptotic’ TAp73 observed in many cancers and its 
physiological function has long been an open debate. However, recently, evidences have 
emerged showing that over-expression of TAp73 can contribute to tumorigenesis.  p53 is 
known to inhibit telomerase, an enzyme  that inhibts cell cycle arrest and apoptosis 
activated by shortened telomeres (Kusumoto M et al., 1999). TAp73 was shown to 
abrogate the p53-mediated suppression of telomerase by reducing p53 levels through the 
activation of Mdm2 E3 ubiquitin ligase (Toh WH et al., 2005). This shows that TAp73 
can also oppose p53 functions, hence possibly contributing to tumorigenesis. Another 
study has demonstrated that gastrin, a peptide hormone that is associated with the 
progression of a number of human malignancies can be transcriptionally regulated by 
p73. Consistently, over-expression of p73 was correlated with high gastrin expression in 
gastric tumors (Tomkova K et al., 2006). Previously, our laboratory has shown that upon 
genotoxic stress, c-Jun expression stabilizes TAp73 to promote cell death (Toh WH et al., 
2004). Conversely, we have also shown that TAp73 can co-operate with c-Jun to induce 
cell proliferation and survival via the transcriptional activation of several AP-1 target 
genes such as cyclin D1 and collagenase, further demonstrating the dual role of p73 in 
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cancer development (Vikhanskaya F et al., 2007). Additionally, both TAp73β and 
DNp73β are able to specifically transactivate the expression of the anti-apoptotic member 
of the caspase family, caspase-2S (Toh WH et al., 2009). Over-expression of DNp73β 
led to elevated levels of caspase-2S and resistance to cell death, showing that p73 may be 
over-expressed in cancers to promote survival. Finally, a recent report has further 
strengthen this view by illustrating that p73 as well as p63 but not p53 can support 
cellular proliferation through the transcriptional activation of genes involved in G1-S and 
G2-M progression (Lefkimmiatis K et al., 2009).  
It is noteworthy that TAp73-/- knock mice develop spontaneous tumors (Tomasini R et 
al., 2008) and p73/p53 heterozygous mice have an increase tumor burden compared to 
p53 heterozygous mice (Flores ER et al., 2005), indicating that TAp73 works as a classic 
tumor suppressor, probably in non-stressed or genotoxic stress-induced situations. 
However, the recent data clearly indicate that TAp73 can acquire pro-survival role, and 
one can speculate this probably happens in distinct physiological environments such as 
upon non-genotoxic stresses or in combination with proto-oncogenes or mutated proteins 
such as mutated Ras. 
The dual and opposing function of p73 is surprising but not uncommon as several 
transcription factors such as c-myc and c-Jun have also been shown to have both 
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1.10 p73 and autophagy 
A novel function of p73 that has emerged over the past couple years is in mediating 
autophagy. Autophagy can be defined as a membrane trafficking process that mediates 
the delivery of cytoplasmic constituents to the lysosome for degradation (Klionsky DJ et 
al., 2000). The components of the molecular machinery responsible for autophagy are 
products of the autophagy-related (Atg) genes (Illustration 1.3). Autophagy marker Light 
Chain 3 (LC3) undergoes post-translational modifications during autophagy. LC3-I is 
converted to LC3-II through a lipidation process involving several Atg genes that enable 
LC3-I to associate with autophagic vesicles. The presence of LC3-I in autophagosomes 
and its conversion to the lower migrating form LC3-II are used as indicators of autophagy 













Illustration 1.3 Schematic showing the regulation of autophagy process. (Adapted from Cell Signaling 
Technology® website) 
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Autophagy has been linked to many diseases either as a causal or a preventive factor 
(Levine B and Kroemer G, 2008). How does autophagy process contribute to tumor 
biology is unclear. Autophagy maintains a homeostatic balance of protein and organelles 
in the cells in response to their physiological environment and it can be triggered by 
various stimuli such as hypoxia and nutrient deprivation (Klionsky DJ et al., 2000). 
Interestingly, autophagy has been shown to play a role in both cell death and cell survival 
(Codogno P and Meijer AJ, 2005; Yu L et al., 2008), depending on the cellular 
environment. For example, in response to nutrient deprivation, autophagy can act as a 
survival mechanism, by degrading bulk cytoplasm and organelles for energy production, 
hence providing a self-limited supply of ATP to prolong viability (Mizushima N et al., 
2008). However, autophagy has also been described to promote cell death in certain 
settings either when apoptosis is compromised or when it is activated in combination 
with other apoptotic signals (Maiuri MC et al., 2007; Eisenberg-Lerner A et al., 2009). 
Therefore, depending on physiological context, autophagy works either as an oncogenic 
or tumor promoting tool in cancer development. 
The first clue that p73 could be involved in autophagy was its ability to transactivate 
damage-regulated autophagy modulator (DRAM), also a target gene of p53 (Crighton D 
et al., 2007). However, it was shown that p73-mediated autophagy is not via DRAM 
activation but is dependent on its transcription ability, indicating that p73 might be 
targeting other autophagy-related genes. Moreover, unlike p53, p73-mediated induction 
of autophagy did not lead to programmed-cell death in their system, suggesting distinct 
functions. Subsequently, another study showed that p73 could regulate autophagy upon 
serum starvation (Rosenbluth JM et al., 2008). This process was dependent on p73 
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regulation by up-stream mammalian target of rapamycin (mTOR) kinase signaling 
pathway. Inhibition of mTOR by rapamycin or RNAi, led to an increase in p73 levels, 
resulting in the activation of autophagy-associated genes. The same group subsequently 
showed by chromatin immunoprecipitation analyses that p73 could bind to the promoter 
sequences of several autophagy-related genes such as atg5 and atg7 (Rosenbluth JM and 
Pietenpol JA, 2009). But how and under what cellular context does p73 regulate these 
genes remains unknown. 
 
1.11 Transcriptional regulation of p73 
The expression of TAp73 from the P1 promoter is regulated by oncogenic stress via the 
activation of transcription factors E2F-1 and viral oncoprotein E1A. TAp73 is 
transcriptionally up-regulated by E2F-1, a G1/S cell cycle regulated protein (Stiewe and 
Putzer, 2000). E2F-1 activates TAp73 transcription by binding directly to E2F sites 
within the P1 promoter (Seelan RS et al., 2002).  E2F-1 sits together on TAp73 promoter 
in a complex of other transcription factors namely C-EBPα, which has a repressive effect 
on TAp73 transcription under non-stressed state. However, upon DNA damage C-EBPα 
is removed from this complex, allowing the transcription of TAp73 to ensue (Marabese 
M et al., 2003). Similarly, E1A expression increases the level of both TAp73 mRNA and 
protein and this activation is enough to induce apoptosis in tumor cells (Zaika AI et al., 
2001).  TAp73 expression can also be transcriptionally induced by p53 from the P1 
promoter, which contains several p53 potential binding sites (Chen X et al., 2001). 
However, p53 is not involved in the up-regulation of TAp73 upon DNA-damage 
exposure (Marabese M et al., 2003). Interestingly, both TAp73 and p53 can induce 
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DNp73 expression via a p53-responsive element found in the P2 promoter, hence 
creating a negative-feedback loop mechanism to control the activity of both TAp73 and 
p53 (Grob TJ et al., 2001). This implies that DNp73 mRNA levels increases after DNA 
damage that would activate TAp73 and p53. However, it has been shown that DNp73 
expression is subsequently down-regulated at the protein level to release its dominant 
negative effect on TAp73 and p53, allowing apoptosis and cell cycle to ensue (Maisse C 
et al., 2004). The above shows that the same gene can generate both TAp73 and DNp73 
and their individual expression can be regulated in a distinct manner. 
 
1.12 Regulation of p73 activity 
p73 activity can be regulated by many DNA damaging agents via the activation of several 
signal transduction pathways as well as interaction with a panoply of other proteins 











Illustration 1.4 Summary of key known regulators of p73  (Adapted from Marabese M. et al., 2007) 
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c-Abl was the first kinase shown to regulate p73 activity in response to gamma irradiation 
and doxorubicin (Agami R et al., 1999; Yuan ZM et al., 1999; Gong JG et al., 1999). c-
Abl has been shown to induce the phoshorylation of Tyrosine99  on p73 which promotes 
its binding to the prolyl isomerase Pin1. This association in turn enhances the acetylation 
of p73 by histone acetyltransferase p300, leading to conformational changes of p73 that 
potentiate its apoptotic activity (Mantovani F et al., 2004).  c-Jun N-terminal kinases 
(JNKs) are a group of kinases activated by a multitude of stress signals including growth 
factors, inflammatory cytokines and genotoxic stresses, which lead to apoptosis, cell 
proliferation and cell differentiation (Davis RJ, 2000). JNK signaling has been implicated 
in the p73-mediated apoptosis in response to DNA damaging agent cisplatin (Jones EV et 
al., 2007). JNKs induce the phosphorylation of several serine/threonine residues on p73 
upon cisplatin treatment, resulting in the stabilization of p73 as well as its transcriptional 
activity. Additionally, p73 has been found to associate and co-localize with the 
homeodomain-interacting protein kinase 2 (HIPK2) protein in nuclear bodies (Kim EJ et 
al., 2002). Expression of HIPK2 increases the transcriptional repression ability of p73 on 
multidrug-resistant (MDR) and collagenase gene promoters in SAOS2 cells but has no 
effect on p21 and other p53 target gene promoters, hence enhancing the transcriptional 
repressive activity of p73 on selected genes. The checkpoint kinase 1 (Chk1) is an 
essential component of the DNA damage checkpoint and has been shown to 
phosphorylate p73α upon DNA damage leading to the up-regulation of p73α 
transactivation activity (Gonzalez S et al., 2003).  Moreover, a recent report has 
demonstrated that TAp73α, which has weaker transactivation ability than TAp73β, can 
be cleaved by the serine protease HtrA2 in the C-terminal area upon apoptotic stimuli 
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(Marabese M et al., 2008). This leads to increase p73 activation of apoptotic gene bax but 
not cell-cycle regulator gene p21, illustrating yet another way that p73 activity can be 
regulated. In addition, p73 transcriptional activity can be regulated via the interaction 
with ASPP1 and ASPP2 (Bergamaschi D et al., 2004). TAp73 is bound both in vitro and 
in vivo to these two proteins causing enhance TAp73 transcriptional activity on promoters 
of apoptotic genes such as Bax, PIG3 and PUMA but not on cell cycle arrest gene p21 
and Mdm2. 
Conversely, besides activation of p73, phosphorylation by several kinases can negatively 
regulate p73 functions. The Yes-associated protein, YAP, a potent co-activator of p73-
dependent transcription, can be inhibited in an AKT-dependent manner (Basu S et al., 
2003). YAP is phosphorylated by AKT, leading to its association with 14-3-3 protein and 
subsequent export outside the nucleus. This process removes YAP from p73, leading to 
the suppression of its pro-apoptotic ability in response to cellular damage. p73 has also 
been shown to bind to protein kinase A catalytic subunit beta (PKA-Cβ) (Hanamoto T et 
al., 2005). Over-expression of PKA-Cβ significantly inhibits the transactivation function 
and pro-apoptotic activity of p73 upon DNA damage via the intra-molecular interaction 
between the N-terminal transactivation and C-terminal inhibitory domains of p73α. 
Moreover, p73 expression is regulated during cell cycle and was found to interact with 
various cyclins (A, B, D, and E), which resulted in its phosphorylation at threonine86 by 
cyclin A/CDK1/2, cyclin B/CDK1/2 and cyclin E/CDK2 (Gaiddon C et al., 2003). This 
phosphorylation event led to a repression of p73 induction of p21 in a cell-cycle 
dependent manner. Both PLK1 and PLK3, members of the Polo-like kinase family 
members that are involved in the regulation of cell cycle progression and DNA damage 
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response, have been shown to have inhibitory effect on the transcriptional activity of 
TAp73 (Koida N et al., 2008; Sang M et al., 2009).  Both kinases bind and phosphorylate 
TAp73 at the N-terminal leading to the down-regulation of its pro-apoptotic as well as 
cell cycle arrest responses. Hck, a member of the src family of kinases, can interact and 
phosphorylates TAp73 at tyrosine28, resulting in the stabilization of p73 protein (Paliwal 
P et al., 2007). However, over-expression of Hck represses the transcriptional activity of 
p73 on targets such as Mdm2 and also inhibits p73-mediated apoptosis. 
Taken together, these findings show that p73 activity is highly regulated by several 
signaling pathways and phosphorylation by kinases can have both positive and negative 
effect on p73 activity. 
 
 
1.13 Regulation of p73 levels 
Post-translation modifications of p73 are key regulators for its expression and function in 
cells. Protein degradation is a post-translational regulatory mechanism that allows cells to 
fine-tune the levels of critical proteins in response to intracellular signals and changing 
environmental conditions. One major degradation pathway in eukaryotes involves the 
ubiquitin-proteasome system (UPS), where proteins are poly-ubiquitinated and 
subsequently targeted to the 26S proteasome for destruction (Kerscher O et al., 2006) 
(Illustration 1.5). Additionally, besides the classical UPS, p73 levels are also regulated by 
several alternative methods involving degradation via the proteasome but without the 
need for ubiquitination. The fact that p73 is not mutated but over-expressed in cancers 
has been the major drive over the past few years to study the different cellular 
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mechanisms known to control the turnover of proteins and their role in regulating p73 
































1.13.1 Ubiquitin and ubiquitin-like related mechanisms 
Ubiquitination involves the sequential transfer of activated ubiquitin, a 76 amino acid 
protein, between a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme 
(E2) and a ubiquitin–protein ligase (E3) (Kerscher O et al., 2006). E3 ubiquitin ligases 
facilitate the transfer of ubiquitin lysine (Lys) residues in the substrate and the type of 
ubiquitination and the ubiquitin chains formed determine the fate of the protein. 
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Ubiquitin itself contains seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 
and Lys63) and so far, Lys48- and Lys63-type polyubiquitin chains have been the most 
well-studied. Targets that contain Lys48-linked ubiquitin chains are usually degraded by 
the 26S proteasome, whereas monoubiquitylation and polyubiquitylation via other lys-
type chains are involved in a number of different cellular non-proteaosomal processes, 
such as endocytosis and vesicular sorting (Ravid T and Hochstrasser M, 2008). 
Several E3 ubiquitin ligases are associated with p73 degradation as well as proteins that 
regulate p73 levels indirectly via the ubiquitination process. Mdm2, a key E3 ubiquitin 
ligase that regulates the level of p53 in a negative feed-back manner (Wu X et al., 1993), 
has been shown to bind to TAp73 at the transactivation domain via amino acid residues 
found to be conserved in both TAp73 and p53 (Balint E et al., 1999; Zeng X et al., 1999). 
Even though Mdm2 expression can be up-regulated by TAp73, it does not induce the 
degradation or ubiquitination of TAp73, but can inhibit its transcriptional activity. Pirh2, 
a recently identified E3 ubiquitin ligase that is induced by p53 in a similar fashion to 
Mdm2 and causes its degradation, has been demonstrated to have no significant effect on 
the steady-state of p73 (Leng RP et al., 2003). NEDL2, a NEDD4-type E3 ubiquitin 
ligase, has been reported to interact with both p73α and p73β via the proline-rich (PY) 
region at the C-terminal of the protein (Miyazaki K et al., 2003). Interestingly, NELD2 
induces the ubiquitination of TAp73 but does not lead to its degradation. On the contrary, 
this process increases the stability and the transcriptional activity of TAp73, indicating 
that there exists a non-proteolytic regulatory role of ubiquitination on p73. The tumor 
suppressor promyelocytic leukemia protein, PML, together with p38 MAPK, has been 
shown to enhance the stability of p73 upon chemotherapeutic drugs treatments such as 
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doxorubicin, by inhibiting the ubiquitination of p73 and subsequently regulating p73 
transcriptional activity via PML-nuclear bodies (Bernassola F et al., 2004). RanBPM, a 
Ran nuclear–cytoplasmic transport protein binding protein, was fouind to interact with 
the extreme C-terminal region of p73α (Kramer S et al., 2005). RanBPM was shown to 
increase the stability of p73α by inhibiting its ubiquitination leading an increase in p73α 
pro-apoptotic activities. Nuclear factor kappa B (NF-κB) has been shown to play an 
important role in cell survival processes (Beg AA and Baltimore D, 1996). In a recent 
study, NF-κB was found to induce the ubiquitin-dependent proteasomal degradation of 
pro-apoptotic p73α (Kikuchi H et al., 2006). Ectopic expression of NF-κB decreased the 
half-life of p73α, thereby inhibiting its transcriptional and pro-apoptotic activities. 
Moreover, the same authors subsequently showed that induction of nuclear IKK-α by 
cisplatin treatment led to its binding and stabilization of p73 in a kinase-dependent 
manner (Furuya K et al., 2007). IKK-α inhibited the ubiquitination of p73α leading to its 
increase transcriptional and pro-apoptotic activities. c-Jun is a member of the AP-1 
family of transcription factors that regulate genes controlling proliferation, differentiation 
and apoptosis (Eferl R and Wagner EF, 2003). Extracellular signals, including growth 
factors, oncoproteins and genotoxic stresses activate c-Jun via phosphorylation at 
Serine63 and Serine 73 by JNKs (Eferl R and Wagner EF, 2003).  Upon 
chemotherapeutic drug treatment, c-Jun expression induces the stabilization of TAp73 by 
inhibiting its proteasome-mediated degradation, resulting in the potentiation of p73-
mediated transcriptional activity towards apoptosis (Toh WH et al., 2004). Itch, another 
NEDD4-type E3 ubiquitin ligase, has been shown to interact with both TAp73 and 
DNp73 via the PY motif (Rossi M et al., 2005). This binding leads to the ubiquitination 
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and degradation of p73 forms in unstressed cells. Upon exposure to DNA-damaging 
agents such as doxorubicin and cisplatin, Itch is degraded leading to the stabilization of 
TAp73 but not DNp73, indicating the presence of alternative degradative mechanisms 
that regulate the levels of DNp73 upon genotoxic stress. FBXO45, an SCF-type E3 
ubiquitin ligase was recently demonstrated to bind to p73 leading to its degradation in a 
proteasome dependent manner (Peschiaroli A et al., 2009). FBXO45 was able to 
ubiquitinate p73 both in vivo and in vitro and interestingly, chemotherapeutic agents such 
as doxorubicin led to the down-regulation of FBXO45 protein similar to Itch, suggesting 
another level of control for p73 expression in response to stress. However, DNp73 was 
equally not affected, pointing again to an unidentified degradation pathway specific for 
DNp73. The Yes-associated protein 1 (YAP1) was first shown to associate with p73 
through its WW domain and the PPPY motif of p73 leading to an increase in the latter’s 
steady-state (Strano S et al., 2001). A possible mechanism was proposed involving Itch 
E3 ligase whereby upon DNA-damage, Yap1 level increases in parallel to the 
degradation of Itch. And since both YAP and Itch shares the same binding site on p73, 
there is a competition, which results in less Itch binding to p73 and hence increased 
stability (Levy D et al., 2007). Another study has shown that YAP is a transcriptional 
target of c-Jun and it has speculated that c-Jun-mediated stabilization of TAp73 is due to 
the same competition mechanism between YAP and Itch at the PPPY motif of p73 
(Danovi SA et al., 2007).  
Besides ubiquitin, two other ubiquitin-like molecules have been demonstrated to regulate 
p73 levels in cells. p73α steady-state levels are regulated by conjugation with the small 
ubiquitin-like modifier, SUMO-1 via the process of sumoylation at the C-terminal (Minty 
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A et al., 2000). Sumoylation of p73 attenuates its transcriptional activity but no 
sufficiently to significantly silence the overall transactivation functions of TAp73α. It is 
noteworthy that sumoylation is specific to the α-forms and also it does not induce the 
degradation of p73 but possibly alters its cellular localization (Minty A et al., 2000). 
NEDD8 is an 81-amino acid polypeptide that shares >50% homology to ubiquitin and the 
NEDD8 conjugation to its substrates relies on the enzymatic pathway composed of the 
NEDD8 E1-activating enzyme, E2-conjugating enzyme (Ubc12) and E3 ligases (Rabut G 
and Peter M, 2008). Until recently, the only identified substrates regulated by this 
pathway were cullins, which are scaffold proteins responsible for the assembly of RING 
finger-type E3 ubiquitin ligases and neddylation of cullins increase the ubiquitination 
activity of these ligases (Rabut G and Peter M, 2008). First evidence that indicated the 
neddylation pathway could regulate p73 levels was obtained using a cell line containing 
temperature labile Nedd8 activation enzyme and inactivation of the enzyme led to an 
accumulation of p73 protein (Bernassola F et al., 2004). Subsequently, another study 
showed that TAp73 and not DNp73 is modified by NEDD8 on the N-terminal in an 
Mdm2-dependent manner, leading to a decrease of TAp73 transcriptional activity 
(Watson IR et al., 2006). However, the effect of this neddylation was observed to 
stabilize TAp73, contradicting the earlier reports.  
 
1.13.2 Ubiquitin-independent mechanisms 
Cyclin G, a member the of cyclin family and a transcriptional target gene of both p73 and 
p53, was the first protein shown to have a negative effect on the stability of p73, 
independent of the ubiquitination process (Ohtsuka T et al., 2003). It was found that 
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cyclin G interacts with p73 and mediates its degradation in an ubiquitin-independent 
proteasome-independent manner. However the precise mechanism of this process still 
remains elusive. Subsequently, another ubiquitin-independent proteasome-dependent 
degradation mechanism of p73 was identified involving the NAD(P)H quinone 
oxidoreductase 1  (NQO1) pathway (Asher G et al., 2005). NQO1 binds to p73α at the 
SAM domain in an NADH-dependent manner and the majority of NQO1 in cells are 
associated with the 20S proteasome. It has been proposed that NQO1 act as a gatekeeper 
to the 20S proteasome, blocking p73α protein from proteasomal degradation in response 
to gamma-irradiation. UFD2a, a U-box-type E3/E4 ubiquitin ligase has also been shown 
to associate with the SAM domain of p73α leading to its degradation via the proteasome 
in an ubiquitin-independent manner (Hosada M et al., 2005). Interestingly, UFD2a is 
down-regulated upon cisplatin treatment to allow the stabilization of TAp73, indicating 
that not all ubiquitin ligases bound to p73 can induce its poly-ubiquitination and/or 
degradation. Finally, calpain cleavage has recently been demonstrated to regulate the 
stability of p73 (Munarriz E et al., 2005).  Calpain I can digest p73 at the N-terminal 
proline-rich region and at the oligomerization domain, hence able to regulate the levels of 
both TAp73 and DNp73. The above facts clearly show that TAp73 and DNp73 can be 
regulated by distinct mechanisms and a balance of these proteins is crucial in dictating 
the cellular outcome in response to stress and other external stimuli. 
 
1.14 Antizyme-mediated degradation pathway 
Antizyme is a small protein known to mediate the proteasomal degradation of some 
proteins independent of the ubiquitination process (Mangold U, 2005). Until recently, the 
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only protein degraded by this pathway was ornithine decarboxylase (ODC). ODC is the 
rate-limiting enzyme in polyamine biosynthesis pathway and it catalyzes the conversion 














Illustration 1.6 Schematic showing the polyamine biosynthesis pathway. (Adapted from Wallace H.M. 
et al., 2003) 
 
Putrescine is then further converted into other type of polyamines such as spermidine and 
spermine by a series of catalytic enzymes. Polyamines are abundant multivalent organic 
cations largely bound to negatively charged molecules in cells such as to RNA and DNA. 
These molecules are essential for normal cell growth and differentiation as well as in cell 
proliferation and in the development of cancer (Pegg AE and Feith DJ, 2007). 
Polyamines are synthesized in all tissues but can also be transported into cells from 
external sources such as the intestine through food intake. 
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1.14.1 Regulation of antizyme levels  
Interestingly, antizyme levels are regulated by the polyamine pathway, hence creating a 
negative-feedback loop mechanism to maintain a cellular homeostasis. A unique 
ribosomal frameshift mechanism is needed for the expression of functional antizymes 
(Matsufuji S et al., 1995; Coffino P, 2001) (Illustration 1.7). All antizymes have two 
overlapping open reading frames (ORFs), a short ORF1 with a translational start codon 
and a stop codon at the frameshift site and a longer ORF2, which encodes most of the 















Illustration 1.7 Schematic showing the regulation of antizyme processing by polyamines.  (Adapted 
from Coffino P, 2001) 
 
Therefore, translation of a functional, full-length antizyme requires a +1 ribosomal 
frameshift, which is induced primarily by polyamines via a mechanism that is not 
completely understood. The antiviral and antiproliferative agent, interferon, was 
subsequently demonstrated to also increase antizyme production (Le Roy F et al., 2005). 
Interferon induces expression of RNAase L, an endoribonuclease, which interacts with 
the human translation termination factor eRF3 and this association enhances the 
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translation read-through and frameshift efficiency at the antizyme +1 frameshift site. 
Recently, it was further shown that the frameshifting event leading to the production of 
antizyme could be stimulated by the yeast prion protein [PSI+] (Namy O et al., 2008). 
[PSI+] corresponds to the aggregated conformation of the translational release factor 
eRF3 and it increases ribosomal pause at the stop codon of ORF1 to facilitate the 
frameshifting process. 
 
1.14.2 Types of antizyme and their physiological roles 
In humans, there at least three members in the antizyme family and the most well studied 
member is antizyme 1 (Mangold U, 2005). The original function associated with 
antizyme 1 is to induce the degradation of ODC via the 26S proteasome in an ubiquitin-
independent manner (Murakami Y et al., 1992). Antizyme1 binds to ODC to form ODC-
antizyme heterodrimers thereby preventing the association of ODC subunits to form 
active ODC dimers (Coffino P, 2001) (Illustration 1.8). Interaction with antizyme 1 
induces a conformational change in ODC, resulting in the exposure of a C-terminal 
domain that serves as the proteasome recognition signal. During this process, antizyme 1 
is released and can participate in subsequent cycles of ODC degradation, hence tightly 
regulating the polyamine biosynthesis pathway (Coffino P, 2001). Additionally, antizyme 
1 can inhibit polyamine uptake into cells and stimulates polyamine excretion but the 
precise mechanisms by which these processes occur remains unknown (Mitchell JL et al., 
1994; Wallace HM et al., 2003) (Illustration 1.6). Several studies have shown that 
antizyme 1 can negatively regulate cell growth and hence may function as a tumor 
suppressor. Over-expression of antizyme 1 has been shown to suppress cell proliferation 
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and induce apoptosis by inhibiting ODC activity in several in vitro systems (Murakami Y 
et al, 1994; Koike C et al., 1999; Iwata S et al., 1999). Using in vivo models, antizyme 1 
















Illustration 1.8 Schematic showing the degradation of ODC by antizyme.  (Adapted from Coffino P, 
2001) 
 
transformed NIH-3T3 cells or malignant keratinocytes co-expressing antizyme 1 (Iwata S 
et al., 1999). Moreover, transgenic mice expressing antizyme1 under control of the 
keratinocytes K5 or K6 promoters have lower frequency of carcinogen-induced skin 
tumors and fore-stomach cancer compared to control mice (Feith DJ et al., 2001; Fong 
LY et al., 2003). The fact that Az1 is a potential tumor suppressor was further 
strengthened by several studies, which have demonstrated that antizyme activity was 
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dramatically down-regulated in several cancers namely oral tumors, gastric carcinomas 
and prostate cancers (Tsuji T et al., 1998; Koike C et al., 1999; Jung MH et al., 2000). 
Antizyme 2 expression has the same tissue distribution as antizyme1 but is much less 
abundant and although it does not promote ODC degradation in vitro (Ivanov IP et al.,  
1998), antizyme 2 in able to regulate polyamine uptake in cells (Zhu C et al., 1999). 
Further experiments are needed to assess the contribution of antizyme 2 in polyamine 
biosynthesis as well as in cell proliferation and/or apoptosis.  
The expression of the third member of the antizyme family, antizyme 3, is testis specific 
and restricted to certain stages of spermatogenesis (Ivanov IP et al., 1998). Antizyme 1 
and 2 expressions are negligible during spermatogenesis suggesting that antizyme 3 has 
evolved to function specifically during spermatogenesis. However, a recent study has 
shown that antizyme 3 can also inhibit polyamine uptake and ornithine decarboxylase 
(ODC) activity without inducing its degradation (Snapir Z et al., 2009), indicating that 
the antizyme family members have a much more expanded role in regulating cellular 
homeostasis than previously thought. 
 
1.14.3 Regulation of antizyme activity by antizyme inhibitor (AZI) 
All members of the antizyme family can be inactivated by a protein called the antizyme 
inhibitor (AZI), which shares high homology with ODC but lacks any enzymatic activity 
(Mangold U and Leberer E, 2005). Antizymes bind to AZI with higher affinity than ODC 
and causes the release of ODC from the inhibitory interaction with antizyme, leading to 
ODC stabilization (Pegg AE, 2006) (Illustration 1.9).  AZI is rapidly induced in growth-
stimulated mouse fibroblasts and is up-regulated in certain forms of human cancers 
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suggesting a possible role for AZI in tumorigenesis (Nilsson J et al., 2000). However, the 
precise function of AZI during physiological and pathological processes has not been 













Illustration 1.9 Schematic showing role of antizyme inhibitor (AZIN) in inhibition of antizyme-
mediated degradation of ODC. (Adapted Pegg A.E., 2006) 
 
1.14.4 Other known substrates of antizyme1 
For a long time, ODC has been the only protein known to be regulated by antizyme-
proteasome degradation pathway.  However, recently, new targets of antizyme have been 
discovered. By a yeast 2-hybrid screen, direct interactions between antizyme 1 and Smad 
1 as well as between antizyme 1 and the proteasomal subunit HsN3 were found, forming 
a ternary complex (Lin Y et al., 2002). It has been suggested that antizyme 1 and HsN3 
are involved in targeting Smad 1 for proteasomal degradation. In another study, it was 
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shown that antizyme 1 could specifically bind to cyclin D1 leading to degradation by 26S 
proteasome (Newman RM et al., 2004). Moreover, a stable mutant form of cyclin D1, 
which cannot be degraded via the ubiquitin pathway, was rapidly degraded in the 
presence of antizyme 1, indicating that the existence of non-redundant pathways in 
regulating cyclin D1 levels. Aurora-A kinase interacting protein 1 (AURKAIP1), a 
negative regulator of Aurora-A, can promote the proteasome-dependent degradation of 
Aurora-A via antizyme1 (Lim SK and Gopalan G, 2007). AURKAIP1, Az1 and Aurora-
A can exist as a ternary complex and the authors proposed that AURKAIP1 might 
function upstream of Az1 to enhance the interaction between Az1 and Aurora-A, leading 
to the latter’s degradation. 
Notably, both cyclin D1 and Aurora-A levels are known to be regulated by ubiquitin-
dependent degradation and therefore under what physiological conditions do their 
antizyme-mediated degradation mechanism operates is not clear. p53 family of tumor 
suppressors is highly regulated by the ubiquitin proteasome system but nothing is known 
whether they can also be regulated by this non-canonical antizyme degradation pathway. 
However, the above studies clearly show that many proteins can be regulated by both 
type of degradation mechanisms to adjust their levels in cells and the preference of one 
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1.15 Aims 
An interesting feature of the two main forms of p73 is that they are regulated by 
genotoxic stresses in distinct manners. The pro-apoptotic TAp73 is often up-regulated 
upon exposure to DNA-damaging agents such as UV and chemotherapeutic drugs. On the 
other hand, the dominant-negative oncogenic DNp73 is rapidly degraded under similar 
circumstances, expectedly to allow the tumor suppressive functions of TAp73 and p53.  
Therefore it is clear that a balance between TAp73 and DNp73 might play a role in 
tumorigenesis and understanding the mechanisms that regulate this balance is vital. How 
cells destroy oncogenic DNp73 upon genotoxic stress insults has long been elusive.  
Hence, the aim of the first part of this PhD study is to elucidate the mechanism by which 
DNp73 is degraded upon exposure to genotoxic stresses. 
 
It is also becoming increasingly evident that non-DNA damaging stresses such as 
hypoxia play an important role in cancer onset, development and progression. Hypoxic 
conditions are often observed in many solid tumors and for cancerous cells to continue to 
proliferate, they trigger several transcriptional responses that translate into survival 
signals. p53 has been shown to have an apoptotic effect under hypoxia, hence often is 
silenced in cancers. However, p73, the other member of the p53 family, is known to be 
highly up-regulated in many tumors. 
- Hence, the aim of the second part of this PhD study is to understand the effect of the 
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2.1 Materials 
2.1.1 Antibodies 
Table 1 Antibodies used in this study 
Name Description Dilution factor Source 
Primary Antibodies    
ER15 (Ab-3) Monoclonal 1:1000 Oncogene 
GC15 (Ab-2) Monoclonal 1:1000 Oncogene 
HA (Y-11) Polyclonal 1:2000 Santa Cruz 
HA (HA-7) Mouse ascites 1:2000 Santa Cruz 
FLAG (M2) Monoclonal 1:2000 Stratagene 
Itch Monoclonal 1:1000 BD Transduction 
c-Jun (H-79) Polyclonal 1:1000 Santa Cruz 
c-Jun (60A8) Polyclonal 1:1000 Cell Signaling 
p27 (C-19) Polyclonal 1:1000 Santa Cruz 
Cyclin D1 (H-295) Polyclonal 1:1000 Santa Cruz 
Actin Polyclonal 1:3000 Sigma 
GFP (FL) Polyclonal 1:1000 Santa Cruz 
Ub (P4D1)  1:1000 Santa Cruz 
Az1(p) Serum 1:1000 Gift from Mitchell JL.
JNK1/2 Monoclonal 1:1000 BD Pharmigen 
His (H-15) Polyclonal 1:2000 Santa Cruz 
LC3 (APG8b) Polyclonal 1:500 Abgent 
AMPKα  1:1000 Cell Signaling 
Phospho-c-Jun (Ser 63) Polyclonal 1:1000 Cell Signaling 
p44/42 MAPK (ERK1/2) Polyclonal 1:2000 Santa Cruz 
Phospho-p44/42 MAPK  
(ERK1/2) (E10) 
Monoclonal 1:2000 Cell Signaling 
V5 Monoclonal 1:2000 Invitrogen 
VHL Monoclonal 1:500 BD Pharmigen 
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p53 (D0-1) Monoclonal 1:1000 Santa Cruz 
    
Secondary Antibodies    
Anti-mouse IgG, HRP-linked  1:10000 Sigma 
Anti-mouse IgG, HRP-linked  1:2000 Cell Signaling 
Anti-rabbit IgG, HRP-linked  1:10000 Sigma 
Anti-rabbit IgG, HRP-linked  1:2000 Cell Signaling 
 
 
2.1.2 Biochemical inhibitors 





Cycloheximide Protein synthesis inhibitor 50 µg/ml Sigma 




20-40 µM Biogenova 






1 mM Santa Cruz 
Okadaic acid 
Protein phosphatase 1 and 2A 
inhibitor 
50 nM Sigma 
SP600125 JNK1/2 inhibitor 10 µM Calbiochem 
U1026 MEK1/2 inhibitor 10 µM Cell Signaling 
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2.1.3 Drugs and Treatment used 
Table 3 Drugs and Treatments used in this study 
Name Concentration used Source
Doxorubicin (Doxo.) 5 µM Sigma 
Ultra-violet (UV) 50 J - 
Cisplatin (Cis) 25 µM Sigma 
Etoposide 15 µM Sigma 
Putrescine (Put.) 10-30 mM Sigma 
Cobalt chloride (CoCl2) 100-400 µM Sigma 
Hypoxia 1% O2 - 
Normoxia 21% O2 - 
Starvation 0.1% serum/48hrs - 
 
2.1.4 Cell lines 
Table 4 Cell lines used in this study 
Name Description Culture media Source 
 
H1299 Human non-small cell lung 
cancer cells 
10% DMEM Lab cell bank 
SAOS2 Human osteosarcoma cells 10% DMEM Lab cell bank 
HCT116 Human colon cancer cells 10% DMEM Lab cell bank 
SHSY5Y-
DNp73β 
Human neuroblastoma cells 
stably expressing DNp73β 






Human kidney cancer cells 
expressing dnUbc12 via Tet-
ON system 
10% Tet-free serum+ 
Zeocin 




Human osteosarcoma cells 
expressing DNp73α via Tet-
ON system 
10% Tet-free serum+ 
50 µg/ml Hygromycin 
B 
Gift from Dr. 
Gerry Melino 
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SAOS2-
TAp73β 
Human osteosarcoma cells 
expressing TAp73β via Tet-
ON system 
10% Tet-free serum+ 
50 µg/ml Hygromycin 
B 




c-Jun-/- MEFs expressing c-
Jun via Tet-OFF system 
10% DMEM+ 2 µg/ml 
Puromycin 
Lab cell bank 
Wild-type MEFs 10% DMEM Lab cell bank 
cJun-/- c-Jun knock-out MEFs 10% DMEM Lab cell bank 
Itch-/- Itch knock-out MEFs 10% DMEM Gift from Dr. 
Gerry Melino 
JNK1-/-2-/- JNK1 and JNK2 double  
knock-out MEFs 
10% DMEM Lab cell bank 
p53-/- p53 knock-out MEFs 10% DMEM Lab cell bank 
p53-/-
Mdm2-/- 
p53 and Mdm2 double knock-
out MEFs 
10% DMEM Gift from Dr. 
Gigi Lozano 
p73-/- p73 knock-out MEFs (Both 
TAp73 and DNp73) 




Wild-type MEFs stably 
expressing DNp73β 






Itch knock-out MEFs stably 
expressing DNp73β 






c-Jun knock-out MEFs stably 
expressing DNp73β 







PCR reactions were carried under the following conditions: initial 94°C for 3min, 94°C 
for 35s, 55°C for 35s and 72°C for 35s for indicated cycles. H:human; M:mouse 
Table 5 Sequences and conditions for primers used in this study 
Target Name Cycles
Trip1 (M/H) Fwd: 5’ ACCTCCGGAGGCTGCAGGCACAG 3’ X24 
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Rev: 5’ GTCTACCTTGTTGGGCAGGATCTTG 3’ 
DNp73 (H) Fwd: 5’TGCTGTACGTCGGTGACCCCGCAC 3’ 
Rev: 5’ GTGCTGGACTGCTGGAAAGT 3’ 
X36 
c-Jun (M/H) Fwd: 5’ CTGCTCGTCGGTCACGTTCTTGGG 3’ 
Rev: 5’ ATGCCCTCAACGCCTCGTTCCTCC 3’ 
X30 
Gapdh (M/H) Fwd: 5’ CATTGACCTCAACTACATG 3’ 
Rev: 5’ CTTCTCCATGGTGGTGAAG 3’ 
X24 
Az1 (M/H) Fwd: 5’ ATGGTGAAATCCTCCCTGGAG 3’ 
Rev: 5’ TTCCCTCGCCCACCTGGGATC 3’ 
X24 
Odc (M/H) Fwd: 5’ GACTGAAATACAGTTGGTG 3’ 
Rev: 5’ TCAGATCCAGGAAAGCCAC 3’ 
X27 
Spms (M/H) Fwd: 5’ GTGTTGCTGGACCTTCAGAG 3’ 
Rev: 5’ CAAACTGCTTCGAGTGTAG 3’ 
X27 
Spds (M/H) Fwd: 5’ GAGTTCTCCTACCAGGAGATG 3’ 
Rev: 5’ GTAATAGGACTCCTTGAAGAG 3’ 
X27 
Glut-1 (M/H) Fwd: 5’ TGGATGTCCTATCTGAGCATCGTG3’ 
Rev: 5’CTTTGAAGTAGGTGAAGATGAAGA 3’ 
X24 
Vegf (M/H) Fwd: 5’ATGCCAAGTGGTCCCAGGCTGCAC 3’ 
Rev: 5’ TGTGCTGTAGGAAGCTCATCTCTC3’ 
X26 
TAp73 (H) Fwd: 5’ TCTGGAACCAGACAGCACCT 3’ 
Rev: 5’GTGCTGGACTGCTGGAAAGT 3’ 
X32 
Vhl (M/H) Fwd: 5’ TGGCTCAACTTCGACGGCGAG 3’ 
Rev: 5’ GACCTGACGATGTCCAGTCTC 3’ 
X32 
Bnip3 (M/H) Fwd: 5’ CTGCAGGGCTCCTGGGTAGAACTG3’ 




Fwd: 5’ATGGAGTTGGTGGCGCAGCCACTGGTG 3’ 




Fwd: 5’CTTTGCTGGCAGGCAGCTGGAAG 3’ 
Rev: 5’CTTCCAGCTGCCTGCCAGCAAAG 3’ 
X20 
Cloning-Flag-1-425 Fwd: 5’ X20 
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All siRNAs target human sequences of corresponding gene. 
Table 6 Target sequences for siRNAs/shRNAs used in this study 
Target Sequence Source 
Control 5’ AATTCTCCGAACGTGTCACGT 3’ Qiagen 
Trip1 5’ GGTACATCCTGAAGGTAAA 3’ 1st Base 
c-Jun 5’ AAGAACGTGACAGATGAGCAG 3’ 1st Base 
Az1 5’ GCTGAATGTAACAGAGGAA 3’ 1st Base 
Odc 5’ GGAACGGGCGAAAGAGCTA 3’ 1st Base 
Vhl 5’ ACGATGGGCTTCTGGTTAA 3’ 1st Base 
Ampkα1 5’ GGT TGGCAAACATGAATT G 3’ 1st Base 
Ampkα2 5’ GGT TTCTTAAAAACAGCTG 3’ 1st Base 
Itch 5’ AAGGAGCAACATCTGGATTAA 3’ Qiagen 
c-Jun 
(shRNA) 
SHCLND NM_002228 (clones TRCN0000039591/2/3) Sigma 
Control 
(shRNA) 
SHC002 MISSION® Non-Target shRNA control vector Sigma 
 
2.1.7 Buffers & home-made solutions 
Table 7 Components of buffers and solutions used in this study 
Name Components 
DEPC H2O Add 1ml of 0.1% Diethylpyrocarbonate (DEPC) to 1L 
H O. Incubate overnight and i2 nactivate remaining DEPC 
by autoclaving 
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Freezing medium Add 4ml dimethyl sulfoxide (DMSO) to 36ml FCS 
Lysis (Western blot  
and  Immunoprecipitation) 




50 mM Tris, pH 7.4, 250 mM NaCl, 5 mM MgCl2, 0.5% 
NP-40 
Lysis buffer A (For Ni-NTA 
pulldown) 
6 M Guanidinium-HCl, 0.1M Na2HPO4/NaH2PO4, pH 
8.0, 10mM imidazole 
Wash Buffer I (For Ni-NTA 
pulldown) 
Lysis buffer diluted in 25 mM Tris-HCl at 1:4 ratio, pH 
6.8, 20 mM imidazole 
Wash Buffer II (For Ni-
NTA pulldown) 
25 mM Tris-HCl, pH 6.8, 20 mM imidazole 
Elution buffer ((For Ni-NTA 
pulldown) 
62.5 mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 100 
mM DTT, 0.0005% bromophenol blue + 250 imidazole 
Separating gel (10%)  2.5 ml (30% Acryl/0.8% Bis) , 3.5 ml H O, 1.5 ml 
separating buffer (1.5M Tris pH 8.7,0.4% SDS), 75 ul 
APS, 10 ul TEMED
2
Stacking gel  0.5 ml (30% Acryl/0.8% Bis) , 2.5 ml H O, 1 ml stacking 
buffer (0.5M Tris pH 6.8,0.4% SDS), 15 ul APS, 8 ul 
TEMED
2
6X SDS protein loading dye Stacking Buffer, 3ml glycerol, 1g SDS, 0.93g DTT, 1mg 
bromophenol blue, top up to 10ml with H O2
5X SDS running buffer 15.1g Tris, 72g glycine, 5g SDS, top up to 1L 
Transfer buffer 12.13g Tris, 86.50 Tris, 600ml methanol, top up to 4L 
10X TBS 24.2g Tris, 80g NaCl, adjust pH to 7.6 
Blocking buffer  1X TBS, 5% w/v non-fat dry milk, 0.1% Tween-20 
Primary antibody buffer 1X TBS, 1% w/v BSA, 0.1% Tween-20 
Primary antibody buffer 
(Cell Signaling) 
1X TBS, 5% w/v BSA, 0.1% Tween-20 
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2.1.8 Plasmids 
Table 8 Plasmid constructs used in this study 
Gene Plasmid name Source 
p73 TAp73β Lab gene bank 
 Flag-TAp73β Lab gene bank 
 DNp73β Lab gene bank 
 Flag-DNp73β Lab gene bank 
 HA-DNp73α Lab gene bank 
 DNp73β-292 Lab gene bank 
 Flag-1-425 Generated in this study 
 HA-1-358 Lab gene bank 
 HA-1-249 Lab gene bank 
 Flag -TAp73β-P382A Generated in this study 
c-Jun c-Jun Lab gene bank 
 Flag-c-Jun Lab gene bank 
 Flag-TAM67 Lab gene bank 
 ∆194-331 Lab gene bank 
 Flag-∆1-244 Lab gene bank 
 ∆δ-domain Lab gene bank 
 ∆287-331 Lab gene bank 
 ∆194-223 Lab gene bank 
 5XASP Lab gene bank 
 63A/73A Lab gene bank 
 170F Lab gene bank 
Ub 6XHis-Ubi-WT Gift from Dr.Ganesan Gopalan 
 6XHis-Ubi-48 Generated in this study 
 6XHis-Ubi-KO Gift from Dr.Ganesan Gopalan 
PHDs V5-PHD1 Gift from Dr.Dan Peet 
 V5-PHD2 Gift from Dr.Dan Peet 
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 V5-PHD3 Gift from Dr.Dan Peet 
Az1 HA-Az1 Gift from Dr.Ganesan Gopalan 
 Flag-Az1 Gift from Dr.Ganesan Gopalan 
AZI HA-AZI Gift from Dr.Ganesan Gopalan 
Aurora-A HA-Aurora-A Gift from Dr.Ganesan Gopalan 
VHL HA-VHL Gift from Dr.Catherine Dargemont 
Itch Myc-Itch Gift from Dr.Gerry Melino 
GFP Egfp Lab gene bank 




2.2.1 Mammalian cell culture methods 
2.2.1.1 Culture conditions for cell lines 
All cell lines used and generated in this study and details of culture conditions are 
summarized in Table 4. Unless indicated, all cells were cultured at cultured at 37oC in a 
humidified incubator with 5% CO2. Dulbecco’s modified Eagle’s medium (DMEM) was 
used supplemented with 10% fetal bovine serum (FBS), 100U/mL penicillin (GIBCO), 
10µg/ml streptomycin (GIBCO), 2mM L-glutamine (Sigma) and 1mM sodium pyruvate 
(Sigma). Inducible cells were cultured in similar medium except 10% tetracycline-free 
FBS (Clontech) was used instead. 
 
2.2.1.2 Sub-culturing of cell lines 
Sub-culturing of cells was carried out using 0.125% Trypsin-EDTA. Briefly, when cells 
reach 90% confluency, the medium was discarded and cells were washed gently with 
1XPBS. After removing excess PBS, appropriate amount of trypsin was added for 
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approximately 5mins until cells are dislodged. Cells were resuspended in complete 
medium and centrifuged for 5mins at 1500 rpm at 18oC. Cells pellets were then 
resuspended in fresh complete medium and divided accordingly. 
 
2.2.1.3 Cryopreservation of cell lines 
For cryopreservation, cells were treated as in Section 2.2.1.2. However, cells pellets were 
instead resuspended in freezing medium and transferred into cryovials (NUNC) for 
storage at -80oC or in liquid nitrogen for long-term stocks. 
 
2.2.1.4 Stable cell line generation 
All stable cell lines shown in Table 4 were generated in same way. Cells were seeded in 
10-cm tissue culture plates and transfected with indicated plasmids. 48hrs post-
transfection, appropriate antibiotics were added to the medium and cells were selected 
over a period of 2-3 weeks. Single cell colonies were picked and culture individually. 
Clones expressing selected plasmids were then chosen after verification by western blot 
for further culturing and experiments. Cells were re-selected on antibiotics after every 5 
passages. 
 
2.2.1.5 Induction of tetracycline-controlled cell lines 
Cells stably expressing a tetracycline-ON system were induced with addition of 5 µg/ml 
of doxycycline (Sigma) for indicated time. Cells stably expressing a tetracycline-OFF 
system were kept in doxycycline all the time and induction was carried out by incubating 
cells in doxycycline-free medium. 
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2.2.1.5 Plasmid transfection 
Cells were transfected using Lipofectamine™ and Plus™ reagent (Invitrogen) according 
to the manufacturer’s protocol. In brief, cells were seeded in 6-well plates 24hrs before 
transfection to achieve 60-75% confluency. Indicated plasmids were mixed with 4µl of 
Plus™ reagent and 96µl serum-free medium (SFM) and incubated for 15 mins. 5µl of 
Lipofectamine™ and 95µl SFM were then added to the mix, followed by another 15mins 
incubation. Cells were washed with 1X PBS and incubated with 1ml SFM+transfection 
mix for 3-4hrs. Fresh 10% complete medium was added and cells were cultured for at 
least 24hrs before harvest at indicated time points. Unless indicated, concentration of all 
plasmids used is 0.5 µg. For 6-cm and 10-cm plates, transfection reagents were up-scaled 
accordingly. 
 
2.2.1.6 siRNA transfection 
Cells were transfected using TransMessenger™ Transfection Reagent (Qiagen) according 
to the manufacturer’s protocol. In brief, cells were seeded in 6-well plates 24hrs before 
transfection to achieve 40-55% confluency. 20µM of siRNAs were mixed with 5µl of 
Enhancer and 85µl of EC-R buffer and incubated for 5mins. 15µl of TransMessenger™ 
were then added to the mix, followed by 10mins incubation. Cells were washed with 1X 
PBS and incubated with 1ml SFM+ transfection mix for 3-4hrs. Fresh 10% complete 
medium was added and cells were cultured for at least 48hrs before harvest at indicated 
time points.  
 
2.2.1.7 Drugs and stress treatments 
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All types of drugs/stresses and their concentration/dosage as well as details of other 
treatments performed are indicated in Table 3. Unless indicated, treatment of cells was 
done 24hrs post-transfection.  
 
2.2.1.8 Hypoxic treatment 
Due to lack of proper hypoxic facilities (hypoxic sterile tissue culture hood and cell 
incubator), hypoxia was achieved by incubating cells in a modular incubator chamber 
(Billups-Rothenberg) containing 1% O2 at 37oC for indicated time periods. Chamber 
containing cells was flushed for 1.5mins at 2 PSI with 1% O2 and sealed to create the 
hypoxia conditions. Reoxygenation was carried out by putting hypoxic cells back at 37oC 
in a humidified incubator with 5% CO2 for indicated time points. For half-life 
determination under hypoxia, medium containing cycloheximide was de-gased 2hrs 
before adding to hypoxic cells. Modulator was flushed with 1% O2 in-between every 
harvest at indicated time points. 
 
2.2.2 Molecular biology methods 
2.2.2.1 Bacterial transformation 
Heat shock method was used to introduce DNA into bacteria. DNA was mixed with 50 µl 
of competent bacterial DH5α cells and incubated on ice for 15mins. The bacteria-DNA 
mix was then heat-shocked for 1 min at 42oC, transferred to ice for 5mins followed by 
addition of l ml of LB broth. The mix was then incubated in 37oC shaker for 1hrs before 
either plating on LB Agar plates containing 100µg/ml of ampicillin for selection of single 
colonies or directly in LB Broth containing 100µg/ml of ampicillin for culture. 
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2.2.2.2 Site-directed mutagenesis (SDM) 
SDM was carried out by PCR method using a pair of primers with complementary 
sequences containing the desired change in the nucleotide sequence. PCR was performed 
using 50 ng template plasmid using Pfu enzyme (Stratagene) according to manufacturer’s 
protocol. In brief, template plasmid was mixed with primers and 1µl of 10mM dNTP, 5µl 
of 10X Pfu buffer and 1µl of Pfu enzyme, top up to 50 µl with H20. The conditions for 
PCR were as follow: Activation 95oC for 30 secs, amplification 95oC for 30 secs, 
Annealing 55oC for 30 secs, Extention 68oC for 18 mins and repeated 20X. After PCR, 1 
µl of Dpn1 enzyme (New England Biolabs) was added directly to the PCR mix and 
incubated at 37oC for 2 hrs. 10 µl of the mix was then used for bacterial transformation. 
 
2.2.2.3 DNA sequencing 
DNA sequencing was performed using the ABI PRISM BigDye Terminator v1.1 cycle 
sequencing Ready Reaction Kit (Applied Biosystem). 100ng of PCR products or 200-
500ng of plasmid DNA in a volume of 5ul was mixed with 4µl of BigDye reaction 
mixture, 1µl of 10µM primer and incubated for 30 cycles of 96°C for 10secs, 50°C for 
5secs and 60°C for 4mins. The reaction mixture was precipitated with 10µl of sterile 
H2O, 2µl of 3M sodium acetate and 50µl of 95% ethanol for 15mins and then centrifuged 
at 13000rpm for 20mins. The pellet was washed with 250µl of 70% ethanol and air-dried 
before resuspending in 15µl of ABI loading solution and denatured at 95°C for 5mins. 
Each sample was analyzed on the ABI PRISM 377XL automated sequencer. 
 
2.2.2.4 Mini-preparation of plasmid 
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Plasmids were transformed into competent bacterial DH5α cells and plated out on LB 
Agar plate containing 100µg/ml of ampicillin. Single colonies were then picked and 
grown overnight at 37oC in 5ml LB broth containing 100µg/ml of ampicillin. Plamids 
were extracted using QIAprep Spin Miniprep Kit according to manufacturer’s protocol. 
In brief, the bacteria culture was centrifuged at 5000rpm for 5mins and the bacterial 
pellet was resuspended in 250µl of Buffer 1. The suspension was then lyzed with 250 µl 
of Buffer 2 for 5mins before addition of 350µl of Buffer 3. Solutions were mixed gently 
but thoroughly before being spun at 13000rpm for 10mins. The supernatant was then 
transferred to the spin columns and centrifuged at 13000rpm for 1min. 750µl of Wash 
Buffer was added to the column and let to stand for 5mins. Columns were then spun 2X 
at 13000rpm for 1min to remove excess wash buffer and DNA bound to the column was 
eluted with 30-50µl of either TE buffer (10mM Tris-HCI, pH 8.0, 1mM EDTA) or sterile 
water.  
 
2.2.2.5 Maxi-preparation of plasmid 
Transformed bacteria were cultured as in section 2.2.2.4 but in 250ml of LB broth. 
Plasmids were extracted using NucleoSpin Maxi kit (Macherey Nagel) according to the 
manufacturer’s protocol. In brief, bacterial pellet was resuspended in 10ml Resuspension 
solution, followed by lysis in 10ml Lysis solution for 5mins and neutralized with 10ml 
Neutralization solution. Cloudy precipitate was spun down at 13000rpm for 15mins and 
supernatant was passed through column, which has been pre-equilibrated with 30ml 
Equilibration solution. 60ml of Washing solution was allowed to flow through the 
column before bound plasmid was eluted with 15ml of Elution solution. 10.5ml of 
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isopropanol was added to the elution mix, allowed to stand for 5mins and then spun at 
13000rpm for 30mins. DNA pellet was washed with 70% ethanol and air-dried before 
dissolving in 300-500µl of either TE buffer or sterile water. 
 
2.2.2.6 Cloning of TAp73β deletion construct, Flag-1-425  
Flag-1-425 was amplified by PCR using Pfu enzyme as in section 2.2.2.2. The pair of 
primer used contained restrictions sites BamHI (forward primer) and XhoI (reverse 
primer) at the 5’end respectively. Additionally, sequence of the Flag-tag was also added 
to the forward primer. PCR product was purified using QIAquick PCR Purification Kit 
(Qiagen) according to manufacturer’s protocol and together with the pCDNA3.1 vector, 
both were digested with indicated enzymes for 3hrs. Digested products were run through 
a DNA Agarose gel and desired bands were purified using QIAquick Gel Extraction Kit 
(Qiagen) according to manufacturer’s protocol. Ligation was carried out using Quick 
Ligation™ kit (New England Biolabs) with vector to insert ration 1:3. Ligated products 
were subsequently transformed into competent bacterial DH5α cells and plated on LB 
Agar plates containing 100µg/ml of ampicillin. Single colonies were picked and the 
correct size and identity of clones were verified by restriction digestion and DNA 
sequencing respectively. 
 
2.2.2.7 Quantification of nucleic acid concentration 
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2.2.2.8 RNA extraction 
RNA was extracted using Trizol® reagent (Invitrogen) according to manufacturer’s 
protocol. In brief, cell pellets were lyzed in 1ml Trizol for 10mins. 100µl of 1-Bromo-3-
chloropropane (BCP) (Sigma) was added to the mixture and vortexed for 10secs. The 
suspension was left to stand for 5mins before spun down at 13000rpm for 10min at 4oC. 
The solution separated in two phases and the clear top phase was then transferred to a 
new tube and mixed with equal amount of isopropanol thoroughly by vortexing and left 
to stand for 10mins. The sample was then spun at 13000rpm at 4oC for 30mins and the 
RNA pellet was washed with 70% ethanol before left to air-dry. RNA was dissolved in 
30-50µl of DEPC-treated H2O at 60 oC for 10mins. 
 
2.2.2.9 First-strand cDNA synthesis 
3µg of RNA was used for first-strand cDNA synthesis. The RNA was mixed with 1µl of 
10mM dNTPs and 1µl of oligo-dT (Invitrogen) and topped up with DEPC-treated H2O to 
a total volume of 12µl. The suspension was incubated at 65oC for 5mins followed by 
cooling on ice for 5mins. SuperScript® III Reverse Transcriptase (Invitrogen) was used 
for the next steps. 4µl of Superscript® Buffer, 2µl of 0.1M DTT, 0.5µl of RNaseOUT® 
(Invitrogen), 0.5µl of Superscript® II enzyme and 1µl of DEPC-treated H2O were added 
to the RNA mixture and incubated at 42oC for 1hr. The reaction was terminated by 
heating the first-strand cDNA at 70oC for 15mins. 
 
2.2.2.10 Semi-quantitative PCR 
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Semi-quantitative RT-PCR was performed using Taq polymerase (Qiagen) in a 25µl 
solution according to manufacturer’s protocols. See Table 5 for details of reactions. 
 
2.2.2.11 Quantitative Real-time PCR 
Real-time PCR was carried out using RotorGene 6000 system (Corbett Research) and 
SYBR Green Master Mix (Applied Biosystems). 1µl of cDNA was mixed with 4µl of 
10µM primer mix, 10µl of SYBR Green Master Mix and 5µl sterile H2O (ddH2O). PCR 
cycles were as follow: 95°C for 15mins, 94°C for 15secs, 58-60°C for 30secs, 76°C for 
30secs, 50 cycles starting step two, and followed by melting curve analysis starting from 
65°C to 95°C. The results obtained were analyzed using the RotorGene 4.0 software.  All 
sample Ct values were normalized against gapdh and expressed as 2-∆∆Ct to calculate the 
differences in fold changes. 
 
2.2.3 Protein analytical methods 
2.2.3.1 Extraction of protein lysate 
Cells were harvested similar to section 2.2.1.2. Pellets were re-suspended in 50µl of cold 
protein lysis buffer supplemented with protease inhibitor cocktails (Sigma) and 
phosphatase inhibitor cocktails (Sigma) and incubated on ice for 30mins. The suspension 
was then spun for 30mins at 14000rpm in refrigerated centrifuge and the supernatant was 
collected and used protein concentration measurement 
 
2.2.3.2 Determination of protein concentration 
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Protein concentration was determined using Ultrospec 3000 (Pharmacia Biotech) and 
Bradford method with protein binding dye (Pierce). For measurements, 1µl of protein 
sample was added to 499µl H2O and 500µl of the dye. Readings were recorded at 
wavelength of 595 nm. 
 
2.2.3.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE gels (10-14%) were run using the Mini-PROTEAN® gel apparatus (Bio-rad 
Laboratories). Separating gels were first prepared and allowed to set for 30mins. 
Isopropanol was added on top of the gel during that time to prevent evaporation and 
straighten the top of the gel before addition of stacking gel. Stacking gel was loaded onto 
the separating gel and together the combs, allowed to set for another 30mins. The protein 
samples were boiled in 1X SDS protein before transferring into the wells. The gel was 
typically run at 111V for 2hrs in 1X SDS electrophoresis buffer. A prestained protein 
marker, broad range (New England Biolabs) was run as a reference.  
 
2.2.3.4 Transfer of protein onto membranes 
Proteins were transferred from the gel to membranes using the Mini Trans-Blot® cell 
(Bio-rad Laboratories). Polyvinylidene fluoride (PVDF) (Millipore) membranes were 
activated in methanol and together with gel, incubated in transfer buffer for 15mins 
before being assembled in the transfer cassette. Transfer was typically done at 100V for 
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Once the transfer process was completed, membranes were first soaked in Ponceau S 
solution (Sigma) to verify integrity of transfer. Membranes were then rinsed with sterile 
H2O and incubated for 1hr with blocking solution. Subsequently, membranes were 
washed 2X for 10mins with washing buffer and incubated with primary antibody at 4°C 
overnight with gentle agitation. Primary antibodies were dissolved in either 0.5% BSA 
(all antibodies) or 5% BSA (only for Cell Signaling antibodies). Membranes were then 
washed 3X for 10mins with washing buffer, followed by incubation with secondary 
antibodies for 1hr at room temperature. For Cell Signaling antibodies, secondary 
antibodies were dissolved in 5% milk and all other antibodies, 0.5% milk was used. To 
remove the unbound secondary antibodies, the membranes were washed 3X for 10mins 
with washing buffer before detection using Amersham™ ECL detection reagent or 
SuperSignal™ West Dura Extended duration Substrate (all antibodies) and 20X 
LumiGLO® Reagent and 20X Peroxide (Cell Signaling antibodies).  
 
2.2.3.6 Co-immunoprecipitation (Co-IP) 
Lysates from cells transfected with indicated plasmids were first pre-cleared by 
incubation with 20µl of 50% slurry of either mouse or rabbit IgG-Agarose beads (Sigma) 
for 2hrs, depending on the source of the primary antibody used for IP. This was followed 
by incubation with 20µl of anti-FLAG® M2-Agarose beads (Sigma) for 4hrs at 4°C 
under constant rotation. Beads were then washed 4X with lysis buffer and protein 
complexes were eluted in 2X sample protein loading buffer. Typically, 1000µg protein 
lysate was used for immunoprecipitation experiments and 50µg corresponding 
immunodetection. 
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2.2.3.7 In vivo ubiquitination assay 
For assays using exogenous ubiquitin, cells transfected with the indicated plasmids were 
treated with MG132 before harvesting. Cells were lyzed in 500µl of lysis buffer A and 
the lysate was sonicated for 30secs to reduce viscosity and then mixed on a rotator with 
50µl (settled volume) of Nickel-NTA-Agarose beads (Qiagen) for 3hrs at 4°C. The beads 
were then washed 1X with the lysis buffer A, 1X with Wash buffer I and 2X with Wash 
buffer II. Proteins were eluted by boiling the beads in Elution buffer (refer to Table 7).  
For assays using endogenous ubiquitin, cells were transfected with indicated plasmids 
and ubiquitinated species were immunoprecipitated with either anti-FLAG® M2-Agarose 
beads (Sigma) or anti-HA-Agarose beads (Sigma) similar to protocol described for co-
immunoprecipitation method. Lysis and washing buffers were additionally supplemented 
with 4mM N-Ethylmaleimide (Sigma) to inhibit isopeptidase and deubiquitinase 
enzymes. 
 
2.2.3.8 Protein half-life determination 
Cells were transfected with indicated plasmids for 24hrs prior to addition of 50µg/ml of 
cycloheximide. For half-life determination under stress, cells were pre-treated with 
doxorubicin for 3hrs before addition of cycloheximide and both were maintained 
throughout the collection time points. Quantification of amount of protein remaining was 
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3.1 Background 
We have previously shown that c-Jun, a member of the AP-1 family of transcription 
factors, is able to stabilize TAp73, but not DNp73 (Toh WH et al., 2004). c-Jun is a 
critical regulator of both cellular survival and death, with its levels being elevated upon 
exposure to a multitude of stress signals as well as growth factors (Eferl R and Wagner 
EF, 2003). As exposure to genotoxic stress signals lead to the degradation of DNp73, we 
investigated if c-Jun could have a role in regulating DNp73 stability. 
 
3.2 DNp73 is degraded upon genotoxic stresses 
Reduction of DNp73 levels upon exposure to multiple stress signals was confirmed using 
two different cellular systems. First, we used the p53 null SAOS-2 osteosarcoma cell line 
in which DNp73α was inducibly expressed in a doxycycline-dependent manner, as 
endogenous DNp73 is almost undetectable by available antibodies. Expectedly, UV 
irradiation or treatment with the anti-cancer cytotoxic drug doxorubicin resulted in a 
reduction of DNp73α steady-state levels (Figure 1A). The degradative effect of these 
stresses was further shown by a dosage-dependent assay where an increasing dose of 
doxorubicin or UV led to increase degradation of DNp73α (Figure 1B). Secondly, we 
generated a cell line stably expressing DNp73β in p53 positive SHSY5Y neuroblastoma 
cells. Treatment with a panel of stress signals led to a significant decrease in the levels of 
DNp73β (Figure 1C), further confirming that both DNp73α and DNp73β could be 
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that indeed genotoxic stress-mediated DNp73 degradation occurs through altered protein 
turnover. It is noteworthy that the amount of DNp73 at T=0 in doxorubicin-treated cells 
(for 3hrs) is less than one would expect (<50%) based on the half-life observed for 
DNp73 in doxorubicin-treated cells (~2½hrs), indicating that there might be some 
transcriptional/translational repression induced by doxorubicin together with the post-
translation effect observed. 
 
 
3.4 Stress-induced degradation of DNp73 occurs via the proteasome 
One of the major cellular pathways regulating protein turnover is through the ubiquitin-
proteasome system (UPS) (Kerscher O et al., 2006). Proteins targeted for degradation are 
tagged with polyubiquitin chains by an E3 ligase enzyme and are sent to the 26S 
proteasome complex for destruction. As genotoxic insults led to the degradation of 
DNp73, we asked whether this was happening via the proteasome pathway. DNp73α was 
expressed using the SAOS2-DNp73α inducible cell line and treated with the proteasome 
inhibitor MG132, either 3hrs prior to or 3hrs after exposure to UV and doxorubicin 
(Figure 3A). Either treatment with MG132 inhibited the reduction of DNp73 levels upon 
both stresses, suggesting that the degradation of DNp73 occurs via the proteasome. To 
further confirm the role of the proteasome, we silenced the expression of Trip1/S8/hSug1 
using siRNAs, a critical 19S proteasomal component (Yamada HY and Gorbsky GJ, 
2006) (Figure 3B). This specifically abrogated the reduction of DNp73β after UV 
irradiation or doxorubicin treatment, further confirming that stress-mediated degradation 
of DNp73 indeed occurs via the proteasomal pathway. It is noteworthy that the levels of 
DNp73β in Trip1-silenced cells treated with stresses are higher compared to un-stressed 
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cells and is most likely due to either unequal knock-down efficiency or an additive effect 
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vivo ubiquitination assays in the presence of MG132 revealed that UV irradiation (Figure 



















Figure 4. Genotoxic stress does not increase the amount of exogenous ubiquitin added to DNp73β 
polyubiquitinated species. A-B. DNp73β and 6xHis-ubiquitin plasmids were transfected together with 
Egfp into H1299 cells 24hrs before UV (A) or doxorubicin (B) treatment in the presence of MG132. Cells 
were harvested at indicated time points and lysates were purified through a Ni-NTA Agarose column prior 
to immunodetection (top blots). Whole cell lysates (WCL) were used for detection of steady-state levels of 
transfected proteins (bottom blots). 
 
ubiquitin molecules onto DNp73β up till 6hrs post-treatment, by which time the steady-
state levels had reduced. To rule out any non-specific effect of exogenous ubiquitin used, 
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we carried out similar experiment and detected for endogenous ubiquitination of 
transfected DNp73β from the cells. No increase in the amount of endogenously 
polyubiquitinated DNp73α (Figure 5A) or DNp73β (Figure 5B) was detected, hence 

















Figure 5. Genotoxic stress does not increase the amount of endogenous ubiquitin added to DNp73α 
or DNp73β polyubiquitinated species. A-B. H1299 cells transfected with either HA-DNp73α (A) or 
Flag-DNp73β (B) and Egfp plasmids were treated with UV 24hrs post transfection in the presence of 
MG132. Cells were collected at indicated time points and lysates were immunoprecipitated using anti-
FLAG® M2-Agarose beads (Sigma) or anti-HA-Agarose beads (Sigma) for immunodetection with anti-Ub 
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To further strengthen this conclusion, we inhibited the E1 ubiquitin-activating enzyme 
using the chemical inhibitor, 4[4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-
yl]-benzoic acid ethyl ester (PYR-41) (Yang Y et al., 2007). PYR-41 treatment caused a 
marked increase in p27 levels, a highly labile protein that is degraded via the ubiquitin 
system (Pagano M et al., 1995) (Figure 6A), hence confirming the efficacy of this 
reagent. Doxorubicin treatment of cells transfected with DNp73β and pre-treated with 
PYR-41 did not prevent the degradation of DNp73β (Figure 6B), indicating that a 









Figure 6. Chemical inhibition of E1-activating enzyme does not prevent stress-mediated degradation 
of DNp73. A-B. H1299 cells were treated with 40µM PYR-41 for indicated times (A) or transfected with 
DNp73β and Egfp plasmids 24hrs before PYR-41 treatment for 4hrs prior to doxorubicin treatment for a 
further 6hrs (B) before harvest for immunodetection. PYR-41 was kept in the medium during the stress 
treatment. * non-specific band seen with the anti-p27antibody. 
 
We next assessed if DNp73 could be degraded by stress in the presence of ubiquitin 
mutants that prevent the formation of all types of polyubiquitin chains (all lysine mutants 
[KO]) or Lysine-48 type chains, which are required to mediate ubiquitin-dependent 
proteasomal degradation of substrates (K48R/Ubi-48) (Ravid T and Hochstrasser M, 
2008). Consistently, doxorubicin treatment of cells co-transfected with DNp73β and 
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either ubiquitin mutants did not abrogate the reduction of DNp73β levels (Figure 7A), 
which suggested that the degradation process was indeed independent of ubiquitination.  
The functionality of Ubi-KO mutant was confirmed by in vivo ubiquitination assays 
(Figure 7B), where its over-expression competed with wild-type ubiquitin and 






























Figure 7. Over-expression of ubiquitin mutants does not prevent stress-mediated degradation of 
DNp73 A. DNp73β and Egfp plasmids were transfected with various 6xHis-ubiquitin mutants into H1299 
cells that were UV irradiated 24hrs later and collected for immunodetection. B. H1299 cells were 
transfected with Flag-DNp73β and wild-type 6XHis-ubiquitin in the presence or absence of 6XHis-lysine-
less ubiquitin (Ubi-KO) for 24hrs prior to 6hrs treatment with MG132. Cells were collected and lysates 
were immunoprecipitated using anti-FLAG® M2-Agarose beads (Sigma) for immunodetection with anti-
Ub (top blots). Whole cell lysates (WCL) were used for detection of steady-state levels of transfected 
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Additionally, half-life of DNp73β was assessed when co-expressed with either wild-type 
ubiquitin or Ubi-KO and expectedly, presence of the ubiquitin mutants did not affect the 
decrease in half-life of DNp73 from ~6hrs to ~2½ hrs upon doxorubicin treatment 
(Figure 8A-B). It is noteworthy that level of DNp73β at T=0 in doxorubicin-treated cells 
is slightly higher compared to DNp73β level at T=0 in doxorubicin-treated cells in Figure 
2B, and this might be due a partial inhibitory effect of over-expressed wild-type ubiquitin 





























Figure 8. Half-life of DNp73 is equally reduced upon stress in the presence of wild-type ubiquitin or 
lysine-less mutant ubiquitin. A-B. H1299 cells were transfected with DNp73β and either wild-type 
6XHis-ubiquitin (A) or 6XHis-Ub-KO (B) plasmids together with Egfp. 24hrs post transfection, cells were 
pre-treated with doxorubicin for 3hrs before addition of 50µg/ml cycloheximide and collected at indicated 
time points for immunodetection. Doxorubicin was kept in the medium throughout the experiment. 
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Ubiquitination of p73 for e.g by NEDL2 has previously been shown to have a positive 
effect of the stability of p73 (Miyazaki K et al., 2003). Nevertheless, all of the above data 
therefore strongly demonstrate that DNp73 levels are reduced upon stress treatment in an 
ubiquitin-independent but proteasome-dependent manner. 
 
3.6 Stress-mediated c-Jun induction coincides with DNp73 degradation 
As it appeared that DNp73 degradation may occur via a novel mechanism (independent 
of ubiquitination), we explored alternate possibilities. c-Jun, a key regulator of stress-
mediated death, is up-regulated by several genotoxic stresses and has been shown to 
regulate the abundance of TAp73 (Toh WH et al., 2004). We therefore investigated if c-
Jun would have any role in the reduction of DNp73 levels. Cells were transfected with 
DNp73β and subsequent treatment with doxorubicin, UV or cisplatin led to a clear 
induction of c-Jun expression, concurrent with reduction in DNp73β abundance under 
similar stresses (Figure 9A). A time-course analysis experiment performed using the 
SAOS2-DNp73α inducible cell line also indicated that induction of c-Jun, which occurs 
at ~1hr after exposure to doxorubicin or UV, preceded the reduction in DNp73α levels 
occurring around 4hrs and 2hrs respectively (Figure 9B). Hence, c-Jun expression upon 
stress treatment appears to be associated with the degradation of DNp73. 
 
3.7 c-Jun is required for DNp73 degradation upon stress 
Since c-Jun expression correlated with the degradation of DNp73, we therefore 
proceeded to silence c-Jun expression and determine if its up-regulation by stress would 
be causal to reduction of DNp73 in two cellular systems. First, DNp73α was expressed 
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using the SAOS2-DNp73α inducible cell and c-Jun was silenced using siRNAs prior to 
stress treatment. Reduction in c-Jun levels significantly abrogated the decrease of 
DNp73α levels after UV irradiation or doxorubicin treatment (Figure 10A). Secondly, 
silencing c-Jun expression in cells transfected with DNp73β prior to UV irradiation or 
doxorubicin treatment also alleviated the reduction of DNp73β levels (Figure 10B), 


































 B  
ure 9. c-Jun expression correlates with the degradation of DNp73 upon stress. A. H1299 cells were 
nsfected with DNp73β and Egfp plasmids and treated with the indicated stresses for 6hrs before analysis 
 immunodetection. B. SAOS2-DNp73α cells induced for 24hrs were treated with the indicated stresses 
 harvested at indicated time points for immunodetection.  
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Figure 10. Degradation of DNp73 upon stress is dependent on c-Jun. A. SAOS2-DNp73α cells were 
transfected with either control scramble or c-jun siRNA 24hrs prior to induction of DNp73α expression for 
24hrs. Cells were then treated with indicated stresses for 6hrs prior to harvest for immunodetection. B. 
H1299 cells were transfected with either control scramble or c-jun shRNAs 24hrs prior to transfection with 




3.8 Stress-mediated degradation of DNp73 is dependent on c-Jun but not on Itch 
It has previously been reported that the E3 ubiquitin ligase Itch could regulate the levels 
of p73 upon genotoxic stresses (Rossi M et al., 2005). Additionally, Itch has also been 
shown to regulate the level of c-Jun after T-cell stimulation (Gao M et al., 2004). 
Therefore, we evaluated the role of Itch in DNp73 degradation upon stress treatment. 
Silencing of Itch expression using siRNAs did not affect DNp73β degradation upon 
doxorubicin treatment (Figure 11A). To further confirm this observation, we assessed the  
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Figure 11. Stress-mediated degradation of DNp73 is dependent on c-Jun but not on Itch. A. H1299 
cells were transfected with either control scramble or itch siRNA 24hrs prior to transfection with DNp73β 
and Egfp plasmids. 24hrs later, cells were treated with doxorubicin and harvested at indicated time points 
for immunodetection. B. Wild-type, c-jun-/- and itch-/- MEFs stably expressing DNp73β were UV irradiated 




stability of DNp73 in mouse embryonic fibroblasts (MEFs) proficient or deficient in Itch 
or c-Jun, by generating cells stably expressing DNp73β. UV irradiation led to a 
significant reduction of DNp73β levels in both wild-type and in itch-/- cells, but this was 
not observed in c-jun-/- cells up to 24hrs after UV irradiation (Figure 11B), implying that 
stress-induced DNp73 degradation occurs primarily through c-Jun in mouse cells. 
Moreover, absence of c-Jun did not affect Itch levels suggesting that c-Jun-mediated 
regulation of DNp73 levels could occur independent of Itch. It is notable that c-Jun 
induction upon stress is less pronounced in itch-/- cells compared to wild-type at earlier 
time points. However, being a potent negative regulator of DNp73, this is sufficient to 
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induce DNp73β degradation, which is comparable to wild-type cells at T=24hrs, albeit at 
a slower kinetics. Together, the data further demonstrate that c-Jun is critical for the 
reduction of DNp73 levels upon exposure to genotoxic signals in both mouse and human 
cells. 
 
3.9 c-Jun expression results in the degradation of DNp73 
Whether expression of c-Jun alone could directly lead to DNp73 degradation was next 
analyzed, by transiently co-expressing c-Jun with either TAp73β or DNp73β. Just as it 
has previously been reported that c-Jun expression stabilizes TAp73β (Toh WH et al., 
2004), DNp73β levels was down-regulated in the presence of c-Jun (Figure 12A). 
Moreover, c-Jun expression caused a marked decrease in the levels DNp73β even with 
increasing amounts of DNp73β, suggesting that c-Jun may be a potent negative regulator 
of DNp73 abundance  (Figure 12B). Furthermore, the levels of R292H-DNp73β, a DNA-
binding domain mutant, was also reduced in the presence of c-Jun (Figure 12C), 
indicating that c-Jun could regulate DNp73 levels independent of the latter’s DNA-
binding ability. Additionally, we assessed the effect of c-Jun on the two major forms of 
DNp73 using two cellular systems. Firstly, c-Jun was co-transfected in cells with either 
DNp73α or DNp73β and the levels of both DNp73 forms were markedly reduced in the 
presence of c-Jun (Figure 13A). Moreover, c-Jun expression did not affect the level of 
transfected DNp73 transcripts, indicating that degradation of DNp73 is not due any effect 
of c-Jun on DNp73 mRNA stability (Figure 13B). Secondly, DNp73α or DNp73β was 
transfected in a c-Jun inducible cell line and subsequent induction of c-Jun expression by 
removal of doxycycline resulted in a reduction of DNp73 levels over time (Figure 13C). 
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ure 12. Over-expression of c-Jun leads to the degradation of DNp73. A-C. H1299 cells were 
nsfected with Egfp and either TAp73β or DNp73β plasmid in combination with c-Jun (A) with c-Jun and 
reasing concentration of DNp73β plasmid (0.5µg, 1µg, 2µg) (B) with either DNp73β or DNp73β-292 
smid in combination with c-Jun (C). Cells were harvested 24hrs later for immunodetection. Ratio of 
p73 and c-Jun was kept at 1:3 unless indicated. 
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Figure 13. Both DNp73α and DNp73β are degraded by c-Jun. A-B. H1299 cells were transfected with 
either DNp73α or DNp73β plasmid in combination with c-Jun together with Egfp. Cells were harvested 
24hrs later for immunodetection (A) or RT-PCR analysis (B). C. DNp73α or DNp73β plasmids were 
transfected into the c-Jun-inducible cell line prior to induction of c-Jun (by removal of doxycycline 
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3.10 c-Jun expression results in the decrease in half-life of DNp73 
We next sought that the change in steady-state level of DNp73 upon c-Jun expression 
was due to the altered protein stability, half-life measurements of DNp73 was carried out. 
Half-life of DNp73β was dramatically reduced from ~6hrs to ~2hrs in the presence of c-
Jun similar to what was observed after stress treatment (Figure 14), indicating that c-Jun 



























Figure 14. Over-expression of c-Jun reduces the half-life of DNp73. H1299 cells were transfected with 
either DNp73β or in combination with c-Jun together with Egfp for 24hrs prior to treatment with 50µg/ml 
cycloheximide. Cells were harvested at indicated time points for immunodetection (upper panel). Graph 
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3.11 Knock-down of c-Jun increases the steady-state level of DNp73 
To further verify the role of c-Jun in regulating DNp73 abundance, we proceeded to 
silence the expression of endogenous c-Jun using siRNAs and observe the effect on 
transfected DNp73. Expectedly, absence of c-Jun resulted in an elevated expression of 
both DNp73α and DNp73β (Figure 15), further confirming that c-Jun is a negative 
















Figure 15. Steady-state of DNp73 is higher in the absence of c-Jun. H1299 cells were transfected with 
either control scramble or c-jun siRNA 24hrs prior to transfection with DNp73α or DNp73β plasmid 




3.12 Itch-mediated degradation of DNp73 is independent of c-Jun 
Finally, we evaluated if c-Jun was acting independent of Itch in the degradation of 
DNp73. Co-expression of Itch with DNp73β led to a dramatic reduction of DNp73β level 
in wild-type MEFs, as previously reported (Figure 16) (Rossi M et al., 2005). Similar 
results were obtained with c-jun-/- MEFs, indicating that DNp73 can be degraded by both 
Itch and c-Jun, albeit through distinct pathways. Altogether, these results demonstrate 
that c-Jun expression is capable of destabilizing DNp73 in several cellular systems. 
 77
















Figure 16. c-Jun is not required for Itch-mediated degradation of DNp73. Wild type and c-jun-/- MEFs 





3.13 Transactivation domain and region spanning amino acids 194-223 of c-Jun 
are required for c-Jun-mediated degradation of DNp73 
We next investigated what structural components of c-Jun were required for degradation 
of DNp73 by transfecting several deletion mutants of c-Jun with DNp73β. All but three 
mutants namely TAM67 (only the transactivation domain is deleted), ∆1-244 and ∆194-
223 were able to degrade DNp73β (Figure17). Both TAM67 and ∆1-244 lack the 
transactivation domain of c-Jun, indicating that the transactivation ability of c-Jun might 
be required for the DNp73 degradation. Interestingly, even though the ∆194-223 c-Jun 
mutant lacking a relatively glutamine-rich region contains an intact transactivation 
domain, it was unable to reduce DNp73β levels. Additionally, TAM67, which has the 
glutamine-rich region, was also unable to down-regulate DNp73β showing that both 
these regions of c-Jun are important for its ability to degrade DNp73. 
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Figure 17. Structural requirements c-Jun-mediated degradation of DNp73. H1299 cells were 
transfected with either DNp73β or in combination with indicated c-Jun mutant plasmids together with Egfp 





3.14 Degradation of DNp73 by c-Jun is independent of its c-Abl and JNK 
phosphorylation sites 
Two of the key regulators of c-Jun activity upon stress stimulation are c-Jun N-terminal 
kinases (JNKs) (Musti AM et al., 1997) and c-Abl kinase (Barila D et al., 2000). JNKs 
are activated upon stress signals and lead to the activation of c-Jun by phosphorylating its 
serines 63 and 73 amino acid residues (Musti AM et al., 1997). On the other hand, c-Abl 
activates c-Jun by inducing its phosphorylation at tyrosine170 upon exposure to DNA-
damaging agents (Barila D et al., 2000). Hence, we next evaluated the relevance of any 
of these phosphorylation sites in c-Jun-mediated degradation of DNp73. c-Jun mutant 
(63A/73A), where the serines have been changed to alanines and mutant (170F), where 
the tyrosine has been mutated into phenylalanine, could degrade DNp73β similar to wild-
type c-Jun (Figure 18).  Conversely, a c-Jun mutant (5xASP), where several 
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phosphorylation sites, including those for JNKs, were replaced with the phospho-mimetic 
aspartic acid residues, was also able to degrade DNp73 showing that phosphorylation at 
those sites do not affect c-Jun ability to degrade DNp73. These data indicate that JNKs 















Figure 18. c-Abl and JNK phosphorylation sites are not important for c-Jun-mediated degradation of 
DNp73. H1299 cells were transfected with either DNp73β or in combination with indicated c-Jun mutant 




3.15 Degradation of DNp73 by c-Jun occurs in the absence of JNK1/2 
To completely rule out the involvement of JNKs in c-Jun-mediated degradation of 
DNp73, we transfected JNK double-knockout cell line (JNK1-/-2-/-) with DNp73β and 
an increasing amount of c-Jun. The levels of DNp73β were dramatically reduced with 
increasing c-Jun expression in both wild-type and JNK1-/-2-/- MEFs (Figure 19), 






















Figure 19. JNKs are not required for c-Jun mediated degradation of DNp73. Wild type and jnk1-/-2-/- 
MEFs were transfected with either DNp73β alone or with an increasing concentration of c-Jun plasmids 




3.16 Degradation of DNp73 by c-Jun does not occur through Mdm2 and TAp73 
Similar to p53, E3 ubiquitin ligase Mdm2 has been shown to interact with p73 (Balint E 
et al., 1999; Zeng X et al., 1999). Although there are data showing conflicting evidence 
on the ability of Mdm2 to regulate the steady-state of p73, it is generally believed that 
Mdm2 can not degrade p73.  Additionally, it has been postulated that TAp73 can induce 
the degradation of DNp73 via an unknown auto-feedback loop mechanism (Dulloo I and 
Sabapathy K, 2005). Since c-Jun expression has been shown to stabilize TAp73 (Figure 
12) (Toh WH et al., 2004), to exclude the involvement of Mdm2 or TAp73 in c-Jun-
mediated degradation of DNp73, double knock-out cell line of p53 and Mdm2 (p53-/-
Mdm2-/-) and p73 knock-out cell line (p73-/-) were transfected with DNp73β and c-Jun. 
DNp73β levels were markedly reduced in the presence of c-Jun in all cell lines (Figure 
20), confirming the redundancy of Mdm2 and TAp73 in c-Jun-mediated degradation of 
DNp73. 
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Figure 20. Mdm2 and TAp73 are not required for c-Jun-mediated degradation of DNp73. Wild type, 
p53-/-, p53-/-Mdm2-/- and p73-/- MEFs were transfected with either DNp73β or in combination with c-Jun 





3.17 Over-expression of antizyme-1 (Az1) degrades DNp73 
As there is a lack of physical interaction between c-Jun and p73 (Toh WH et al., 2004), 
we explored other possibilities through which c-Jun could regulate p73 levels. As we 
have shown that degradation of DNp73 by c-Jun is independent of the ubiquitin system 
but dependent on the proteasome, we sought for alternative mechanism via which such a 
phenomenon could occur. Antizyme (Az) belongs to a class of proteins that is involved in 
ubiquitin-independent protein degradation via the proteasome (Mangold U, 2005). We 
therefore co-expressed DNp73β with the cDNA encoding for the processed form of Az1, 
an established member of the Az family, and observed a significant reduction in the 
steady-state level of DNp73β  (Figure 21A). Similar effect of Az1 was seen on Aurora-A, 
another protein whose abundance is negatively regulated by Az1 (Lim SK and Gopalan 
G, 2007).  We next assessed the effect of Az1 on both DNp73α and DNp73β and indeed, 
Az1 could reduce the levels of both forms (Figure 21B), confirming that Az1 can down-
regulate the steady-state levels of DNp73.  
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 B  
ure 21. DNp73 is degraded by antizyme-1. A. H1299 cells were transfected with processed HA-
izyme1 (Az1) and Egfp plasmids in combination with either DNp73β or Aurora-A plasmids together 
th Egfp for 24hrs prior to harvest for immunodetection. The +1 frameshift mutation has been removed 
owing the expression of a functional Az1 protein by the HA-Az1 plasmid. B. H1299 cells were 
nsfected with either DNp73α or DNp73β plasmid in combination with HA-Az1 plasmid together with 
fp. Cells were harvested 24hrs later for immunodetection. 
8 Knock-down of antizyme-1 prevents stress-mediated and c-Jun-mediated 
degradation of DNp73 
nce Az1 appears to be an equally potent negative regulator of DNp73, we next 
aluated its role in stress-mediated or c-Jun-mediated degradation of DNp73 by 
encing the expression of Az1. Whereas DNp73β levels were reduced dramatically 
on doxorubicin treatment in control siRNA treated cells, this was partially inhibited in 
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Az1 siRNA treated cells (Figure 22A). Interestingly, c-Jun levels were still induced by 
doxorubicin treatment in both cases, suggesting that Az1 may act downstream of c-Jun to 
regulate DNp73 abundance. This was confirmed by silencing Az1 expression that 



































Figure 22. DNp73 is not degraded by stress and c-Jun in the absence of antizyme-1. A-B. H1299 cells 
were transfected with either control scramble or Az-1 siRNA 24hrs prior to transfection with DNp73β and 
Egfp plasmids. Cells were either treated with doxorubicin for 6hrs (A) or co-transfected with c-Jun plasmid 
(B) prior to immunodetection. Silencing efficiency of Az-1 siRNA is shown at the bottom of each blot by 
RT-PCR analysis. 
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3.19 Expression of naturally occurring antizyme inhibitor (AZI) prevents stress-
mediated and c-Jun-mediated degradation of DNp73 
To further establish the role of Az1 in stress-mediated and c-Jun-dependent DNp73 
degradation, we utilized the natural inhibitor of Az1, AZI (Mangold U and Leberer E, 
2005). Co-expression of AZI and DNp73β prior to doxorubicin treatment reduced the 
degradation of DNp73β (Figure 23A).  Similarly, co-expression of AZI with c-Jun and 
DNp73β prevented the down-regulation of DNp73β levels by c-Jun (Figure 23B), 
suggesting that Az1 is indeed required for stress-mediated and c-Jun-mediated 
























Figure 23. DNp73 is not degraded by stress and c-Jun in the presence of antizyme-1 inhibitor, AZI. 
A-B. H1299 cells were transfected with DNp73β, HA-AZI and Egfp plasmids and either treated with 
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3.20 Degradation of DNp73 by antizyme-1 occurs downstream of c-Jun 
Antizyme-1 mediates the degradation of proteins in a ubiquitin-independent manner 
(Mangold U, 2005). In order to confirm that Az1-mediated degradation of DNp73 occurs 
downstream of c-Jun, control and c-jun shRNAs-treated cells were transfected with 
DNp73β and Az1. DNp73β levels were markedly reduced in both cases (Figure 24), 















Figure 24. Degradation of DNp73 by antizyme-1 occurs downstream of c-Jun. H1299 cells were 
transfected with either control scramble or c-jun shRNAs 24hrs prior to transfection with DNp73β, HA-





3.21 Degradation of DNp73 by antizyme-1 is independent of the ubiquitin system 
Therefore, to confirm the ubiquitin-independence of this process, we co-expressed Az1 
with DNp73β in the presence of the E1 ubiquitin-activating enzyme inhibitor PYR-41. 
Expectedly, treatment of PYR-41 did not affect the reduction of DNp73β levels by Az1, 
similar to control DMSO-treated cells (Figure 25). This indicates that comparable to the 
stress-mediated degradation of DNp73 (Figure 6), Az1 could indeed cause the 
degradation of DNp73 independent of the ubiquitin system. 
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Figure 25. Antizyme-1 degrades DNp73 in the absence of a functional ubiquitin system. H1299 cells 
were transfected with DNp73β, HA-Az1 and Egfp plasmids for 24hrs prior to treatment with 40µM PYR-




3.22 Antizyme-1 binds to DNp73 
Az1 is known to send its substrates for degradation via direct binding to the target 
proteins and bringing them to the proteasome (Coffino P, 2001). As there is no 
interaction between c-Jun and TAp73 (Toh WH et al., 2004), we next investigated if 
DNp73 and Az1 were able to physically interact with each other. Co-expression of 
DNp73 and Az1, followed by immunoprecipitation of either Flag-Az1 (Figure 26A) or 
Flag-DNp73 (Figure 26B) using Anti-FLAG® M2 beads led to the pull-down of DNp73 
or Az1, respectively, confirming that Az1 and DNp73 can indeed interact in vivo. It is 
noteworthy that one cannot rule out the existence of a ternary complex of c-Jun-Az1-
DNp73. Smad1 and Aurora-A, known targets of Az1, have been shown to form ternary 
complexes with proteasomal subunit HsN3 and AURKAIP1 respectively, for degradation 
(Lin Y et al., 2002; Lim SK and Gopalan G, 2007). Taken together, these data show that 
stress-induced, c-Jun-mediated regulation of DNp73 abundance occurs through Az1. 
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n B re 26. Antizyme-1 binds to DNp73. A-B. H1299 cells were transfected with HA-DNp73α and Flag-
(A) or Flag-DNp73β and HA-Az1 (B) for 24hrs prior to harvest. Cell lysates were used for co-
noprecipitation (IP) using anti-FLAG® M2-Agarose beads (Sigma). Interacting proteins were 
ted using indicated antibodies (top blots). Whole cell lysates (WCL) were used for detection of 
y-state levels of transfected proteins (bottom blots). 
 Genotoxic stress does not regulate the level of antizyme-1 at the 
transcriptional level 
 c-Jun degrades DNp73 via Az1 upon stress stimulation was next analyzed. Since c-
is a transcription factor, and has been shown earlier to require its transcriptional 
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ability for DNp73 degradation (Figure 17), we asked if c-Jun could transcriptionally 
activate Az1. Thus, we analyzed Az1 mRNA levels upon UV irradiation or doxorubicin 
treatment. No changes in Az1 mRNA levels were observed by semi-quantitative RT-PCR 
(Figure 27A) and real-time quantitative PCR (Figure 27B) upon both stresses, even 
though c-jun was induced several folds, indicating that Az1 is probably not a direct target 






















Figure 27. Antizyme-1 is not transcriptionally regulated by stress. A-B. mRNA from doxorubicin or 
UV-treated H1299 cells were collected at indicated time points for semi-quantitative RT-PCR (A) and real-




3.24 ODC mRNA is upregulated in a c-Jun dependent manner upon genotoxic 
stress 
Antizyme1 levels are tightly regulated by the polyamine biosynthesis pathway involving 
key enzymes namely ornithine decarboxylase (ODC), spermine synthase (SPMS) and 
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spermidine synthase (SPDS) (Mangold U, 2006). Hence we evaluated if c-Jun could 
transcriptionally regulate the levels of any of these enzymes upon stress. Both UV-
irradiated H1299 (Figure 28A) and wild-type MEFs (Figure 28B) showed that the 
increase in c-Jun levels correlated with an early increase in odc but not spms and spds 
mRNA levels, indicating that odc could be a direct target of c-Jun. Indeed, UV irradiation 
was previously found to induce the expression of ODC (Rosen CF et al., 1990; 
Braselmann S et al., 1992). To further confirm this observation, both wild-type and c-jun-
/- MEFs were UV-irradiated and interestingly, the induction of odc was abrogated in c-
jun-/- MEFs (Figure 28C), indicating that c-Jun can indeed transcriptionally up-regulate 
ODC in response to genotoxic stress. 
 
3.25 Inhibition of ODC is not sufficient to prevent stress-mediated degradation of 
DNp73 
We next asked if degradation of DNp73 by stress requires ODC. DNp73α was expressed 
using SAOS2-DNp73α inducible cells pre-treated with a chemical inhibitor of ODC, α-
Difluoromethylornithine (DFMO) prior to UV irradiation or doxorubicin treatment. 
Inhibition of ODC did not prevent the stress-mediated degradation of DNp73 (Figure 
29A). Additionally, doxorubicin was able to reduce the levels of transfected DNp7β in 
control siRNA or odc siRNA-treated cells (Figure 29B), further confirming that 



























































ure 28. Genotoxic stress induces the up-regulation of ODC transcripts in a c-Jun dependent 
nner. A-C.mRNA from H1299 (A), wild-type MEFs (B-C) and c-jun-/- MEFs (C) cells treated with UV 
re collected at indicated time points for semi-quantitative RT-PCR analyses. 
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Figure 29. Inhibition of ODC is not sufficient to prevent stress-mediated degradation of DNp73. A. 
SAOS2-DNp73α cells were incubated in 4mM DFMO for 3 days prior to induction of DNp73α expression 
for 24hrs. Cells were then treated with indicated stresses for 6hrs prior to harvest for immunodetection. B. 
H1299 cells were transfected with either control scramble or odc siRNA 24hrs prior to transfection with 
DNp73β and Egfp plasmids. 24hrs later, cells were treated with doxorubicin and harvested at indicated 






3.26 Antizyme-1 regulation by polyamines 
Az1 expression is regulated in a polyamine-dependent manner during translation through 
a programmed +1 frame-shift, resulting in the expression of the functional full-length 
protein (Figure 30A) (Coffino P, 2001). We evaluated if the processed Az1 [Az1 (p)] 
could be induced in our cellular system. Indeed, addition of putrescine, a polyamine 
family member, to wild-type MEFs led to the expression of Az1 (p) that was detected 
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using an antibody that specifically recognizes processed Az1 (Figure 30B) (Mitchell JL et 















Figure 30. Antizyme-1 regulation by polyamines. A. Schematic showing the regulation of Az1 
expression by polyamines at the post-transcriptional level. B. Wild-type MEFs were treated with 10mM 





3.27 Genotoxic stress up-regulates processed antizyme-1 in a c-Jun dependent 
manner 
As we have shown that stress-mediated degradation of DNp73 occurs via c-Jun and this 
required a functional Az1 protein, we next examined if genotoxic stresses could regulate 
the expression of processed Az1 [Az1 (p)] in a c-Jun dependent manner. Similar to 
putrescine addition, doxorubicin treatment (Figure 31A) or UV irradiation (Figure 31B) 
also resulted in the appearance of Az1 (p) in wild-type cells. However, this was not the 
case in c-jun-/- cells, indicating that c-Jun is indeed required for Az1 (p) production after 

































Figure 31. Az1(p) is upregulated upon genotoxic stress in a c-Jun dependent manner. A-B. Wild-type 
and c-jun-/- MEFs were treated with doxorubicin (A) or UV (B) and harvested at indicated time points for 




3.28 Absence of c-Jun does not affect the level of antizyme-1 mRNA after stress 
To confirm that the absence of c-Jun did not affect the levels of Az1 mRNA upon stress, 
we analyzed Az1 mRNA levels in both UV-irradiated wild-type and c-jun-/- cells. 
Relatively equal amount of Az1 mRNA was detected by semi-quantitative RT-PCR 
(Figure 32A) and real-time quantitative PCR (Figure 32B) in both wild-type and c-jun-/- 
cells. Additionally, no change in their levels was observed upon stress treatment, 
confirming the c-Jun-dependent up-regulation of Az1 upon stress is not due to a change 
in Az1 mRNA but due to an increase in post-transcriptional processing of Az1.  
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Figure 32. Antizyme-1 is not transcriptionally induced upon UV irradiation in wild-type and c-jun-/- 
MEFs. A-B. Wild-type and c-jun-/- MEFs were UV irradiated and cells were harvested at indicated time 
points. mRNA was collected and used for semi-quantitative RT-PCR (A) and  real-time quantitative PCR 





3.29 Putrescine induces the degradation of DNp73 in a dosage-dependent manner. 
As putrescine addition induces Az1(p) expression, we hypothesized that the polyamine 
pathway may be involved in DNp73 degradation. This was tested by treating cells 
expressing DNp73β with putrescine, which led to the marked reduction of DNp73β 
















Figure 33. DNp73 is degraded by putrescine. H1299 cells were transfected with DNp73β and Egfp 
plasmids for 24hrs prior to treatment with indicated concentration of putrescine for further 16hrs before 




3.30 Putrescine-mediated degradation of DNp73 is inhibited by proteasome 
inhibitor MG-132 
Since polyamine is able to induce Az1-mediated degradation of its target substrates via 
the proteasome (Coffino P, 2001), we next evaluated if proteasome inhibitor could 
abrogate polyamine-mediated degradation of DNp73. DNp73α was expressed using 
SAOS2-DNp73α inducible cells treated with putrescine and MG132. Indeed, MG132 
was able to prevent the degradation of DNp73α as well as the known target of Az1, 












Figure 34. DNp73 degradation by putrescine is via the proteasome. SAOS2-DNp73α cells were 
induced for 24hrs in the presence of 20mM putrescine for the same time period. Cells were then treated 
with 20µM MG132 for the last 8hrs prior to harvest for immunodetection. 
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3.31 Putrescine-mediated degradation of DNp73 is downstream of c-Jun 
Finally, we assessed if similar to Az1-mediated degradation of DNp73, putrescine-
mediated degradation of DNp73 is downstream of c-Jun. Silencing c-Jun expression by 
shRNAs upon putrescine addition did not prevent DNp73β degradation (Figure 35A). 
Furthermore, putrescine was able to induce Az1(p) expression in the absence of c-Jun 
(Figure 35B), confirming that c-Jun acts upstream of the polyamine pathway. All these 
data together suggest that c-Jun and the polyamine pathway are intricately involved in the 
control of Az1(p) processing, thereby regulating the abundance of DNp73 upon exposure 
to genotoxic stresses. 
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ure 35. Degradation of DNp73 by putrescine is downstream of c-Jun. A. H1299 cells were 
nsfected with either control scramble or c-jun shRNAs 24hrs prior to transfection with DNp73β and 
fp plasmids. Cells were treated with 10mM of putrescine for a further 16hrs prior to harvest for 
munodetection. B. Wild-type and c-jun-/- MEFs were treated with 10mM putrescine for 16hrs prior to 
vest and immunodetection of processed Az1 [ Az1(p)]. 
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Figure 36. Proposed model for regulation of DNp73 by genotoxic stresses. Schematics illustrate the 
proposed mechanism by which genotoxic stresses can induce the degradation of DNp73. c-Jun expression 
is induced by genotoxic insults (UV or doxorubicin). c-Jun up-regulates the +1 frameshift process during 
the translation of antizyme-1 (Az1), probably via modulating the polyamine biosynthesis pathway, 
resulting in the expression of the functional processed antizyme protein (Az1[p]). Az1(p) binds and induces 
the degradation of DNp73 via the proteasome, independent of ubiquitination (left panel). In the absence of 
c-Jun or a defect in polyamine biosynthesis or +1 frameshift mechanism, Az1(p) is not induced upon 
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4.1 Background 
The regulation of p73 levels has mostly been studied in the context of genotoxic stresses. 
The role of p53 tumor suppressor, a homologue of p73, however has been extensively 
investigated both in terms of DNA-damaging stresses, and as well as non-genotoxic 
stresses such as hypoxia (Hammond EM and Giaccia AJ, 2005). Hypoxia is an important 
phenomenon especially in solid tumors and it has been shown to regulate the expression 
of many important transcription factors such as HIF1α (Kaelin WG, 2008). Both TAp73 
and DNp73 are often up-regulated in many such tumors and hypoxic stress activates 
many signaling pathways that have been shown to regulate p73. Hence we decided to 
investigate whether hypoxic stress plays a role in regulating p73 levels in cancer. 
 
4.2 Hypoxic stress up-regulates p73 at the protein level 
In order to assess the effect of hypoxic stress on p73, two different cellular systems were 
employed. First we used HCT116 colon cariconoma cell line to detect any changes in 
endogenous p73 levels upon hypoxia. Since it is technically very challenging to detect 
endogenous p73 by direct western blotting with available antibodies, we 
immunoprecipitated p73 followed by immunoblotting for TAp73. Hypoxic stress resulted 
in an up-regulation of TAp73 (Figure 1A). Concurrently, p53 levels were also increased 
as previously reported (An WG et al., 1998). Both glut-1 and vegf transcripts, well-
established markers of hypoxia, were up-regulated confirming hypoxic conditions were 
achieved (Figure 1B). Low O2   tension did not affect the levels of TAp73 mRNA (Figure 
1B), indicating that increase in TAp73 levels occurred at the protein level. Secondly, we 
used the p53 null SAOS-2 osteosarcoma cell line in which TAp73β was inducibly 
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expressed in a doxycycline-dependent manner and exposure to hypoxic stress also 
resulted in a marked up-regulation in TAp73 levels (Figure 1C), confirming that indeed 





































Figure 1. Hypoxic stress induces the stabilization of TAp73. A-B. HCT116 cells were incubated in 
1% O2 and harvested at indicated time points for immunodetection (A) or semi-quantitative RT-PCR 
analysis (B). Endogenous TAp73 was first immunoprecipitated (IP) with ER15 followed by 
immunodetection with same antibody. IgG of heavy chain and actin levels are shown as loading controls 
for immunoprecipitation and immunoblotting respectively. C. SAOS2-TAp73β cells were induced with 
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4.3 Hypoxic stress up-regulates both TAp73 and DNp73  
We next investigated the effect of hypoxic stress on both TAp73 and DNp73. Exposure 
to low O2 tension led to the stabilization of transfected TAp73β and DNp73β in p53 null 
H1299 non-small cell lung carcinoma cells in a temporal manner (Figure 2A). Increase in 
the levels of vegf and glut-1 transcripts confirmed that hypoxic conditions were achieved 



























Figure 2. Hypoxic stress up-regulates both TAp73 and DNp73. A-B. H1299 cells were transfected with 
either TAp73β (upper panel) or DNp73β (lower panel) plasmids together with Egfp for immunodetection 
(A) or semi-quantitative RT-PCR analysis (B). 24hrs post transfection, cells were incubated in 1% O2 and 
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4.4 Hypoxia mimetic CoCl2 up-regulates p73 in a dosage- and time-dependent 
manner 
To further understand the effect of hypoxic conditions on p73, we utilized cobalt chloride 
(CoCl2), which has been widely used as a hypoxia mimetic agent in both in vivo and in 
vitro studies. Treatment of cells transfected with TAp73β or DNp73β with CoCl2 led to 
their stabilization in both a dose-dependent (Figure 3A) as well as a temporal manner 
(Figure 3C). Increase in the levels of vegf and glut-1 transcripts indicated that hypoxic 
conditions were achieved (Figure 3B, 3D), hence confirming that indeed p73 levels can 
be modulated by hypoxia mimetics. 
 
 
4.5 Stabilization of p73 by hypoxic stress is reverted upon re-oxygenation 
We next asked whether the increase in levels of p73 seen under hypoxic conditions would 
change when cell are re-exposed to normal atmospheric O2 concentration. Expectedly, 
both transfected TAp73β and DNp73β levels were up-regulated in response to the 
hypoxic stress (Figure 4A). Interestingly, upon re-exposure to normoxic conditions, 
TAp73β and DNp73β levels were rapidly suppressed to almost their original levels by 
4hrs (Figure 4A). This down-regulation was paralleled with a decrease in the hypoxic 
markers vegf and glut-1 transcripts (Figure 4B), indicating that p73 levels are reversibly 























































Figure 3. p73 level is up-regulated by CoCl2 in a dosage- and time-dependent manner. A-B. H1299 
cells transfected with either TAp73β (upper panel) or DNp73β (lower panel) plasmids together with Egfp 
were treated 24hrs post transfection with indicated doses of CoCl2 for 8hrs before harvest for 
immunodetection (A) or semi-quantitative RT-PCR analysis (B). C-D H1299 cells were transfected with 
TAp73β for 24hrs before treatment with 200µM CoCl2 and harvested at indicated time point for 

































Figure 4. Re-oxygenation of p73 after hypoxia down-regulates p73 level. A-B. H1299 cells were 
transfected for 24hrs with either TAp73β (upper panel) or DNp73β (lower panel) plasmids together with 
Egfp, followed by incubation in 1% O2 for a further 24hrs. Cells were re-oxygenated (Re-ox.) by incubation 







4.6 Hypoxic stress increases the half-life of p73 
In order to investigate the changes in the steady-state levels of p73 after hypoxic stress 
are due to altered stability of the protein, half-life measurements of TAp73β and DNp73β 
under low O2 tension were carried out using the protein synthesis inhibitor 
cycloheximide. Half-life of TAp73β (Figure 5A) and DNp73β (Figure 5B) were 
dramatically increased after hypoxic treatment from ~3hrs to ~5hrs and from ~6hrs to 
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>9hrs respectively, confirming that hypoxia-mediated up-regulation of p73 occurs as a 









































Figure 5. Half-life of both TAp73β and DNp73β are increased upon hypoxia.   A-B. H1299 cells were 
transfected with either TAp73β (A) or DNp73β (B) plasmids together with Egfp. 24hrs post transfection, 
cells were incubated in 1% O2 for a further 24hrs prior to addition of 50µg/ml cycloheximide and collected 
at indicated time points for immunodetection. Graphs show the quantification of the amount of DNp73 
remaining (lower panels). 
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4.7 Hypoxia decreases the amount of poly-ubiquitinated species of p73 
The turnover of many proteins in cells is regulated by the ubiquitin-proteasome system 
(UPS) (Kerscher O et al., 2006). p73 is a highly ubiquitinated protein and is kept at a low 
level due to rapid degradation. Hence we sought whether the stabilization of p73 upon 
hypoxic stress is due to less ubiquitination of p73. In vivo ubiquitination assay revealed 
that low O2 tension led to a decreased amount of the poly-ubiquitinated species of 
TAp73β, resulting in the concurrent increase in its steady-state levels (Figure 6). This 
indicates that stabilization of p73 upon hypoxia may be due to the inhibition of its 

















Figure 6. Amount of polyubiquitinated p73 species is decreased upon hypoxic stress. H1299 cells were 
transfected for 24hrs with Flag-TAp73β and Egfp plasmids before incubation in 1% O2 for a further 24hrs 
prior to harvest. Lysates were purified using anti-FLAG® M2-Agarose beads (Sigma) for immunodetection 
with anti-Ub (top blot). Whole cell lysates (WCL) were used for detection of steady-state levels of 
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4.8 VHL E3 ubiquitin ligase degrades p73 
One of the classical regulators of hypoxic response is HIF1α (Kaelin WG, 2008). HIF1α 
is kept at low levels during normoxia due to its degradation by VHL E3 ubiquitin ligase. 
Hence we next investigated whether VHL might play a role in regulating the stability of 
p73 under this condition. Co-expression of VHL with TAp73β or DNp73β led to a 
significant decrease in their steady-state levels (Figure 7), indicating that VHL E3 














Figure 7. p73 is degraded by VHL E3 ligase. H1299 cells were transfected with either TAp73β or 






4.9 O2–mediated regulation of p73 is independent of VHL E3 ubiquitin ligase 
As VHL E3 ubiquitin ligase could down-regulate p73 levels, we next analyzed whether 
VHL might play a role in regulating the levels of p73 under different O2 tension. VHL is 
often mutated in many cancers (Barry RE and Krek W, 2004), therefore we verified that 
VHL protein was functional in our cellular systems. Knock-down of VHL in H1299 cells 
(Figure 8A) or SAOS2 cells (data not shown), inhibited the up-regulation of HIF1α 
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targets vegf and glut-1 under hypoxic conditions, confirming both cell lines have a 
functional VHL protein.  However, silencing of VHL in both cellular systems transfected 
with TAp73β did not interfere with either the stabilization by hypoxia or the down-
regulation upon re-oxygenation of TAp73β (Figure 8B-C), indicating that VHL E3 
ubiquitin ligase is not involved in the O2-mediated regulation of p73. VHL is part of a 
cullin-based multi-subunit E3 complex family and to be functional, the cullin protein has 
to be neddylated by the binding of the small ubiquitin-like protein Nedd8 (Rabut G and 
Peter M, 2008). One of the critical enzymes required for the neddylation process is the E2 
conjugating enzyme Ubc12. To unequivocally rule out that VHL might be regulating p73 
under hypoxic conditions, we used HEK293 normal human embryonic kidney cell line in 
which the dominant-negative version of Ubc12 (dnUbc12) was inducibly expressed in a 
doxycycline-dependent manner (Chew EH and Hagen T, 2007).  No differences were 
observed in the O2-mediated regulation of TAp73β (Figure 9A) or DNp73β (Figure 9B) 
in cells expressing dnUbc12. p27, a labile protein which is degraded by a cullin-based E3 
ligase (Pagano M et al., 1995), was up-regulated in the presence of dnUbc12, confirming 
the validity of the system. All the above data clearly suggest that VHL E3 ubiquitin ligase 





















































Figure 8.  O2-mediated regulation of p73 is independent of VHL. A. H1299 cells were transfected with 
either control scramble or vhl siRNA for 24hrs followed by incubation in 1% O2 for a further 24hrs prior to 
harvest for semi-quantitative RT-PCR analysis. B-C. Either control scramble or vhl siRNA was transfected 
into H1299 (B) or SAOS2 (C) cells for 24hrs prior to transfection with TAp73β and Egfp plasmids for 
another 24hrs. Cells were then incubated in 1% O2 for a further 24hrs before re-oxygenation at 21% O2 for 



































Figure 9.  Inhibiting neddylation of VHL E3 ligase complex does not affect the O2 regulation of p73. 
A-B. HEK293-dnUbc12 cells were transfected with either TAp73β (A) or DNp73β (B) plasmids together 
with Egfp for 24hrs. dnUbc12 was induced by addition of doxycycline during incubation in 1% O2 for a 







4.10 O2–mediated regulation of p73 is independent of Itch E3 ligase 
Since VHL E3 ubiquitin ligase do not appear to play a role in p73 modulation by 
different O2 tension, we next investigated if any of E3 ubiquitin ligases known to regulate 
p73 might be involved. Itch has previously been shown to control the levels of p73 upon 
genotoxic stresses (Rossi M et al., 2005) but whether this regulation of p73 can occur 
under non-genotoxic stresses is unknown. Silencing of Itch in cells transfected with 
TAp73β and exposed to different O2 tension did not have any effect the levels of TAp73β 
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Figure 10.  O2-mediated regulation of p73 is independent of Itch. H1299 cells were transfected with 
either control scramble or itch siRNA for 24hrs followed by transfection of TAp73β and Egfp plasmids for 
another 24hrs. Cells were then incubated in 1% O2 for a further 24hrs before re-oxygenation at 21% O2 for 




4.11 p73 contains a putative motif for proline hydroxylation 
In order to get a better understanding of how p73 is regulated by different O2 tension, we 
attempted to identify the structural components of p73 that may be required for this 
process. Since both TAp73β and DNp73β can be stabilized under hypoxia, the N-
terminal transactivation domain of p73 is likely to be dispensable (Figure 2). Hence we 
proceeded to generate several C-terminal truncation mutants of TAp73β and deletion of 
the last 74 amino acids (i.e.1-425) of TAp73β did not significantly affect its stabilization 
upon hypoxic stress (Figure 11A). However, deletion of the next 67 amino acids (i.e.1-
358) completely abolished the up-regulation of TAp73β (Figure 11A), indicating that 
region spanning from 358-425 amino acid residues is crucial for the hypoxia –mediated 
stabilization of p73. 
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We next analyzed the amino acid sequence of that particular region for any known motif 
that might indicate how p73 levels are modulated upon hypoxia. Some proteins that are 
regulated by low O2 tension such as HIF1α, IKKα and IKKβ are hydroxylated at a very 
specific motif (-LXXLAP-) by prolyl-4-hydroxlases (Pavlovich CP and Schmidt, 2004; 
Cummins EP et al., 2006) (Figure 11B). Sequence alignment of region 358-425 of human 
p73 with its homologues showed that this segment is highly conserved in many homologs 
and contains 8 proline and 2 asparagine amino acid residues (Figure 11C). Interestingly, a 
sequence (-L(M/V)ELVP-) highly similar to the known prolyl-4-hydroxlase motif  was 
detected in that same region (Figure 11C), indicating that p73 could also be a target of 
prolyl-4-hydroxlases. Hydroxylation of the proline amino acid residues on HIF1α is 
critical for its degradation under normoxic conditions and mutation of these residues 
abolishes its O2 –mediated regulation, leading to a more stable HIF1α (Kaelin WG, 
2008). Hence we verified the relevance of the proline amino acid residue found in the 
putative motif of p73 in its regulation by different O2 –tension. Mutation of Pro-382 on 
TAp73β into alanine increased its steady-state levels as well as partially inhibited its 
stabilization under hypoxia and degradation upon-reoxygenation (Figure 11D), indicating 

























































Figure 11.  Putative proline hydroxylation motif found between amino acid residues 358-425 of p73. 
A. H1299 cells were transfected with Flag-1-425 or HA-1-358 or HA-1-249 for 24hrs prior to incubation in 
1% O2 for a further 24hrs before harvest for immunodetection.* denote 1-425 obtained after immuodection 
with Flag antibody B. Conserved proline hydroxylation motif (in bold) found in N-terminal and C-terminal 
oxygen-dependent degradation domains (NODD and CODD) of HIFα, IKKα and IKKβ. C. Putative 
proline hydroxylation motif (in bold) found in the region spanning 358-425 amino acid residues of human 
p73 was conserved in rat, mouse, dog and chicken homologues. D. H1299 cells were transfected with 
TAp73β or TAp73β-P382A for 24hrs prior to incubation in 1% O2 for a further 24hrs before re-
oxygenation at 21% O2 for last 4hrs before harvest for immunodetection. 
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4.12 Over-expression of prolyl-4-hydroxylases does not affect p73 levels 
In order to investigate if any prolyl-4-hydroxylases can regulate p73 levels, we co-
expressed TAp73β with three of the prolyl-4-hydroxylases (PHD1, PHD2, PHD3) known 
to regulate HIF1α (Kaelin WG, 2008). The expression of all three types of hydroxylases 
did not lead to the degradation of TAp73β (Figure 12A) or DNp73β (Figure 12B). 
Similar observation was obtained when p73 was co-expressed with FIH-1 (data not 
shown), an asparaginyl hydroxylase that is also involved in the O2–mediated regulation 
of HIF1α (Lando D et al., 2002; Mahon PC et al., 2002), indicating that the HIF1α-
associated hydroxylases do not regulate p73 stability.  
 
 
4.13 Chemical inhibition of prolyl-4-hydroxylases prevent the O2 –mediated 
regulation of p73  
To further assess prolyl-4-hydroxylases involvement in the O2 –mediated regulation of 
p73, we employed dimethyloxaloylglycine (DMOG), a chemical inhibitor of prolyl 
hydroxylase domain-containing proteins, known to up-regulate HIF1α activity (Lando D 
et al., 2002). Treatment of cells transfected with TAp73β and exposed to different O2 
tension in the presence of DMOG completely abrogated the stabilization of TAp73 upon 
hypoxia or degradation upon re-oxygenation (Figure 13A). The efficacy of the inhibitor 
in this experiment was clearly observed as hypoxic targets of HIF1α namely vegf and 
glut-1 transcript levels remained high upon re-oxygenation in cells treated with DMOG 
compared to non-treated cells (Figure 13B). All the above results together indicate that 
possibly an unknown prolyl hydroxylase is regulating the levels of p73 via Pro382, under 
different O2 tension. 
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Figure 12.  Over-expression of prolyl-4-hydroxylases does not down-regulate p73 levels. A-B. H1299 
cells were transfected with either TAp73β (A) or DNp73β (B) in combination with PHD1, PHD2 and 











































Figure 13.  Chemical inhibition of prolyl-4-hydroxylases prevents the O2 regulation of p73. A-B. 
H1299 cells were transfected with TAp73β and Egfp plasmids for 24hrs. 1mM DMOG was added prior to 
incubation in 1% O2 for a further 24hrs before re-oxygenation at 21% O2 for last 4hrs before harvest for 
immunodetection (A) or semi-quantitative RT-PCR (B). 
 
 
4.14 Protein phosphatase 2A is not involved in O2 –mediated regulation of p73 
Protein phosphorylation events play an important role in hypoxia-mediated signal 
transduction pathways (Wang GL et al., 1995). One of the several mechanisms by which 
hypoxic stress regulate the expression of proteins is via the modulation of protein 
phosphatases such as serine/threonine protein phosphatase 2A (PP2A) (Truttmann AC et 
al., 2004). In order to investigate if PP2A has a role in O2 –mediated regulation of p73, 
we employed the chemical inhibitor okadaic acid (OA). Even though OA has been shown 
to inhibit both PP2A and PP1, at low concentration (< 100nM), OA has a higher affinity 
to inhibit PP2A only (Shenolikar S, 1994). The presence of OA did not prevent the O2–
mediated regulation of TAp73β (Figure 14). It is noteworthy that hyper-phosphorylated 
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TAp73β could be observed in cells treated with OA, indicating that p73 may be regulated 














Figure 14.  Protein phosphatase 2A is not involved in O2 –mediated regulation of p73. H1299 cells 
were transfected with TAp73β and Egfp plasmids for 24hrs prior to incubation in 1% O2 for a further 24hrs. 
50nM of okadaic acid (OA) was added to the cells before re-oxygenation at 21% O2 for last 4hrs before 




4.15 c-Jun N-terminal kinases 1 and 2 (JNK1/2) are not involved in O2 –mediated 
regulation of p73 
We next assessed signaling pathways that are involved in both hypoxic response as well 
as p73 regulation. Activation of several MAP kinases such as c-Jun N-terminal kinases 
(JNKs) in response to hypoxia has been demonstrated in different cell types (Laderoute 
KR and Webster KA, 1997). Moreover, JNKs have recently been shown to regulate p73 
levels upon genotoxic stress (Jones EV et al., 2007). Therefore, we investigated whether 
JNKs kinase activities are involved in regulating p73 levels under different O2 tension. 
We utilized the chemical inhibitor SP600125 and its utility was confirmed as SP600125 
abrogated the up-regulation of phosphorylated c-Jun upon UV irradiation (Figure 15A). 
SP600125 treatment of cells transfected with TAp73β did not affect the up-regulation by 
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hypoxia or degradation upon re-oxygenation of p73 (Figure 15B), indicating that JNKs 






















Figure 15.  JNK1/2 are not involved in O2 –mediated regulation of p73. A. H1299 cells pre-treated with 
or without 10µM SP600125 were UV irradiated and cells were harvested after 2hrs for immunodetection. 
B. H1299 cells were transfected with TAp73β and Egfp plasmids for 24hrs. 10µM SP600125 was added 







4.16 Extracellular signal-regulated kinases 1 and 2 (ERK1/2) are not involved in 
O2 –mediated regulation of p73 
Another signaling pathway that is common to both hypoxic stress and p73 is extracellular 
signal-regulated kinases 1 and 2 (ERK1/2). Hypoxia has been demonstrated to activate 
ERK1/2 signaling (Minet E et al., 2000). Additionally, inhibition of ERK1/2 has been 
shown to affect the levels of p73 (Fernandez-Garcia B et al., 2007). Hence we next 
analyzed whether ERK1/2 kinase activities are involved in regulating p73 under different 
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O2 tension. We utilized the chemical inhibitor U0216, which blocks the activation of 
ERK1/2 and its utility was confirmed as U0216 abrogated the up-regulation of 
phosphorylated ERK1/2 in starved cells released in 10% serum (Figure 16A). U0216 
treatment of cells transfected with TAp73β did not affect O2 –mediated regulation of p73 


























Figure 16.  ERK1/2 are not involved in O2 –mediated regulation of p73. A. H1299 cells starved for 
48hrs were pre-treated with or without 10µM U0126 before addition of 10% serum and cells were 
harvested after 3hrs for immunodetection. B. H1299 cells were transfected with TAp73β and Egfp 
plasmids for 24hrs. 10µM U0126 was added prior to incubation in 1% O2 for a further 24hrs before re-




4.17 Inhibition of AMP-activated protein kinase (AMPK) prevents the 
stabilization of p73 upon hypoxia 
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AMPK is considered as a critical sensor for cells under ATP-deprived conditions such as 
hypoxia (Hardie DG, 2007). Hence we next evaluated whether AMPK kinase activity is 
involved in O2 –mediated regulation of p73. Treatment of cells transfected with TAp73β 
with AMPK chemical inhibitor Compound C dramatically prevented the up-regulation of 
TAp73β upon hypoxia but not its down-regulation upon re-oxygenation (Figure 17A), 
indicating that AMPK kinase activity might be required for stabilization of p73 by 
hypoxic stress but not its degradation upon re-oxygenation. It is noteworthy that p73 
basal level at normoxia was also increased, indicating that AMPK may play an inhibitory 
role on p73 levels under normal O2 conditions. To further confirm these observations, we 
proceeded to silence both the catalytic subunits of the AMPKα complex using siRNAs. 
Abrogation of both AMPKα1 and AMPKα2 in cells transfected with TAp73β and 
exposed to hypoxia prevented the up-regulation of TAp73β (Figure 17B), indicating that 
indeed hypoxic stress up-regulates p73 via the AMPK signaling pathway. 
 
4.18 p73 is involved in sustaining hypoxia-mediated autophagy 
A recent study has shown that hypoxia induces autophagy in tumor cells via the 
activation of the AMPK signaling pathway (Papandreou I et al., 2008). Since p73 has 
also been shown to induce autophagy by either over-expression (Crighton D et al., 2007) 
or upon non-genotoxic stress such as serum starvation (Rosenbluth JM et al., 2008), we 
proceeded to investigate if p73 plays a role in the hypoxia-mediated autophagic process. 
Exposure of wild-type HCT116 cells, to low O2 conditions showed an augmentation in 
the autophagic marker LC3 processing, from LC3-I to LC3-II (Figure 18A), indicating 
that hypoxic stress does induce autophagy in our cell system.  Additionally, levels of 
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bnip3, which is known to increase upon hypoxia-mediated autophagy (Bellot G et al., 
2009) as well as hypoxic marker glut-1 were both up-regulated, confirming that 
autophagy observed is indeed due to hypoxic stress. To assess if p73 is involved in 
hypoxia-mediated autophagy, we used mouse embryonic fibroblasts (MEFs) proficient or 
deficient in p73. Exposure to hypoxia induced autophagy in both wild-type and p73-/- 
MEFs as observed by the LC3-I processing and up-regulation of bnip3 (Figure 18B). 
However, the level of LC3-II induction was less pronounced and decreased by 24hrs in 
p73-/- MEFs compared to wild-type MEFs, which correlated with the down-regulation of 
bnip3. This indicates that p73 might be required for sustaining the autophagic process 





























 A B ure 17.  AMPK is required for up-regulation of p73 upon hypoxic stress. A. H1299 cells were 
nsfected with TAp73β and Egfp plasmids for 24hrs. 10µM Compound C was added prior to incubation 
1% O2 for a further 24hrs before re-oxygenation at 21% O2 for last 4hrs before harvest for 
munodetection. B. H1299 cells were transfected with either control scramble or ampkα1+ ampkα2 
NA for 24hrs followed by transfection of TAp73β and Egfp plasmids for another 24hrs. Cells were then 
ubated in 1% O2 for a further 24hrs before harvest for immunodetection. 
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Figure 18.  p73 is involved in sustaining hypoxia-mediated autophagy. A-B HCT116 cells (A) wild-
type and p73-/- MEFs (B) were incubated in 1% O2 and harvested at indicated time points for 
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Figure 19. Proposed model for regulation of p73 by hypoxic stress. Schematics illustrate the proposed 
mechanism by which hypoxic stress can induce the stabilization of p73. Under normoxia, p73 is probably 
hydroxylated by an unknown prolyl-4-hydroxylase (PHD) at Proline382, which leads to its recognition and 
subsequent degradation by an unknown ubiquitin ligase. AMPK signaling is not active under normoxic 
conditions (left panel). Upon hypoxia, prolyl-4-hydroxylase activity is inhibited, p73 is not hydroxylated 
and degraded, leading to its stabilization. Additionally, hypoxia triggers AMPK activation leading to the 
up-regulation of p73 via unknown mechanism (right panel). Hypoxia-mediated stabilization of p73 may 
lead to different survival responses such as autophagy, proliferation or glycolysis. Whether the AMPK 























Chapter 5: Discussion 
 
5.1 Overview 
A unique feature of p73 is that both its distinct forms are differently regulated by stress 
signals. With tumor suppressive properties, TAp73 is often up-regulated upon exposure 
to cellular insults, contributing to cell death. By contrast, DNp73 levels are rapidly 
reduced upon exposure to stress signals, expectedly, to allow the manifestation of 
apoptosis, indicating that selective regulation of the different p73 forms is crucial in 
maintaining the homeostatic balance between life and death of a cell that is undergoing 
genotoxic insults. Thus far, no other regulators of p73 have been identified that perform 
antagonistic functions in regulating the abundance of these different p73 proteins. The 
data presented here therefore provides probably the first example of reciprocal regulation 
of the tumor-suppressor and its dominant negative inhibitor by a common factor, in this 
case, c-Jun. Importantly, the mechanism utilized by c-Jun in the degradation of DNp73 
occurs via a non-classical ubiquitin-independent antizyme-mediated mechanism that is 
often associated with the regulation of polyamine biosynthesis. The data highlight the 
existence of distinct pathways that have probably evolved for the reciprocal regulation of 
the abundance of these functionally different but highly homologous proteins. 
 
5.1.1 Ubiquitin independent mechanism of DNp73 degradation 
Degradation of DNp73α and DNp73β upon genotoxic stress occurred in a ubiquitin-
independent manner via the antizyme pathway. p73 levels have previously been shown to 
be regulated by other ubiquitin-independent mechanisms, namely cyclin G, calpain I, 
UFD2a and NQOI (Ohtsuka T et al., 2003; Munarriz E et al., 2005; Hosada M et al., 
2005; Asher G et al., 2005). The precise mechanism how cyclin G induces the 
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degradation of p73 is currently unknown but the fact that both cyclin G and calpain I can 
down-regulate the levels of either TAp73 or DNp73, indicates that Az1 is unlikely to 
function in the same pathway as cyclin G and calpain I.  UFD2a associates with the C-
terminal SAM domain of TAp73α to degrade it at unstressed state but upon stress, 
UFD2a is down-regulated leading to the stabilization of TAp73α. Similarly, NQOI binds 
to the SAM domain of TAp73α and prevents its proteasomal degradation upon gamma-
irradiation. Since the SAM domain is not required for Az1 to degrade DNp73, it is 
doubtful that NQO1 and UFD2a have a role in the antizyme-mediated degradation of 
DNp73. It is noteworthy to say this mechanism of degradation works only under 
genotoxic stress and that DNp73 could be degraded by the ubiquitin-proteasome pathway 
under different physiological settings. 
 
5.1.2 Degradation of DNp73 by c-Jun
c-Jun is a member of the AP-1 family of transcription factors  and transactivates genes as 
heterodimers through binding of their leucine zipper domains with other members of the 
family mostly c-fos (Eferl R and Wagner EF, 2003). However c-Jun has also been shown 
to work as homodimers, albeit with lesser transactivation potential compared to 
heterodimers (Chinenov Y and Kerppola TK, 2001). Stress-induced degradation of 
DNp73 as well as up-regulation of processed Az-1 was abrogated in the absence of c-Jun 
in all cellular systems tested, indicating that c-Jun alone is sufficient to degrade DNp73. 
However, one cannot completely rule out the role of other AP-1 family members that 
may play a role to potentiate c-Jun activity and function. Additionally, c-Jun may work as 
a co-factor together with a transcriptional complex at the promoter of the target gene 
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involved in triggering the polyamine biosynthesis pathway under stress. A recent report 
has shown that indeed c-Jun can work as a crucial co-factor, where IL-1β locus is 
occupied by PU.1 and C/EBPβ and only the binding of c-Jun to the complex enhances 
RNA Polymerase II recruitment and the efficiency of transcription, allowing for a rapid 
stress response in macrophages (Grondin B et al., 2007). Therefore the role of other AP-1 
family members in regulating DNp73 levels as well as in what transcriptional form does 
c-Jun trigger the DNp73 degradation remain to be investigated. 
Additionally, a glutamine rich region appears to be important for degradative function of 
c-Jun as well. Sequence analysis did not detect any known motifs in that region. 
Moreover, no c-Jun interacting partners are known to bind in that area, hence one can 
speculate that this glutamine-rich region might be important for the structural integrity or 
binding ability of c-Jun to other factors to initiate transcription. Glutamine rich region has 
been shown to be critical in the transcription activity of human transcription factor Sp1 
(Courey AJ and Tijan R, 1988).  This region was subsequently demonstrated to bind to 
TATA-box-binding protein (TBP)-associated factor in the TFIID complex to mediate 
transcriptional activation (Gill G et al., 1994). Interestingly, c-Jun associates with N 
terminus of human TATA-binding protein associated factor-1 (Lively TN et al., 2004), 
indicating that c-Jun might be working in conjunction with the transcription machinery to 
induce the degradation of DNp73. 
DNp73 could be degraded by mutant c-Jun lacking JNK phosphorylation sites as well as 
by wild-type c-Jun in JNK1-/-2-/- cell line, indicating that DNp73 degradation by c-Jun is 
JNK-independent. JNKs are important regulators of c-Jun activity upon stress stimulation 
(Eferl R and Wagner EF, 2003). c-Jun knock-out mice are embryonic lethal (Hilberg F et 
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al., 1993) but c-Jun AA knock-in mice [JNK phosphorylation sites Ser63 and Ser73 have 
both been mutated to alanines (AA)] are viable (Behrens A et al., 1999), indicating that c-
Jun does have phosphorylation-independent functions. Hence, the regulation of Az1 
processing by c-Jun via the polyamine biosynthesis pathway might not require a JNK-
phosphorylated c-Jun. Several studies have shown that indeed c-Jun can regulate gene 
expression independent of phosphorylation at the Ser63 and Ser73 sites (Cruzalegui FH 
et al., 1999; Chen LC et al., 2005). Since the polyamine biosynthesis pathway is 
triggered under genotoxic stress conditions, one might expect the activation of signaling 
cascades involving some kinase. c-Abl, another stress kinase shown to regulate c-Jun 
functions via tyrosine 170 phosphorylation (Barila D et al., 2000) was also not required 
for c-Jun mediated degradation of DNp73, indicating that other kinases might be 
involved in regulating c-Jun function is this particular physiological context.  
c-Jun knock-out mice are embryonically lethal (Hilberg F et al., 1993). The mice die at 
around E13.0 due to defects in the liver and heart development (Eferl R et al., 1999). 
Based on our findings and the fact that DNp73 is highly involved in some embryonic 
developmental processes, one would expect a high level of DNp73 expression in c-Jun 
deficient cells and this might account for some of the phenotypes observed in the mice. It 
has been reported that DNp73 is the predominant form expressed in the developing 
mouse brain as seen by in situ hybridization of E12.5 fetal mouse brain (Pozniak CD et 
al., 2000). However, no data is available on the expression of DNp73 in embryonic liver 
and heart. Once the limitations of endogenous DNp73 detection is overcome, it would be 
exciting to see the level of DNp73 expression in the liver and heart of c-Jun knock-out 
mice as well as to investigate if the crossing these mice with the DNp73 specific knock-
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out mice (currently being characterized) will rescue the defective liver and heart 
phenotypes. Similarly, based on the anti-apoptotic and dominant-negative functions of 
DNp73, it would be interesting to assess if knock-down of DNp73 in c-Jun knock-out 
cells make them more sensitive to apoptotic signals. 
 
5.1.3 Degradation of DNp73 by c-Jun not likely to involve Itch or YAP 
We have previously demonstrated that c-Jun is required for the stabilization of TAp73 
(Toh WH et al., 2005), probably through the transactivation of YAP, which is a positive 
regulator of TAp73 stability (Danovi SA et al., 2008). YAP has been shown to displace 
Itch by competitive binding to TAp73 (Levy D et al., 2007), and hence could be 
responsible for c-Jun-mediated TAp73 stability. However, co-expression of c-Jun with 
DNp73 did not lead to the latter’s stabilization, but on the contrary, led to its degradation, 
although the Itch/YAP binding-site is common to both TAp73 and DNp73. Thus, both 
Itch and YAP may not contribute to c-Jun-mediated DNp73 degradation upon stress 
activation, a notion that is supported by the fact that DNp73 was degraded in itch-/- cells, 
but not in c-jun-/- cells upon exposure to stress. It may seem counter-intuitive that upon 
stress, c-Jun activates both a stabilizer (YAP) and a degrader (Az1) to regulate DNp73. 
However, one can argue that there is a difference in the time of activation of these two 
proteins. Az1 is seen up-regulated within couple hours after stress exposure (this study). 
However, Itch only start to degrade around 24hrs upon similar stress (Rossi M et al., 
2005). Therefore, the competition event between YAP and Itch on DNp73 can only take 
place much a later, by which Az1 has already degrade DNp73 in the cells. 
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5.1.4 Degradation of DNp73 by stress involves antizyme 1 
DNp73 was degraded in an ubiquitin-independent but proteasome-dependent manner 
upon stress activation. We therefore explored other possibilities and found that the 
Az/polyamine pathway is crucial for DNp73 degradation. Over-expression of processed 
Az1, or the physiological activation of the Az pathway by addition of polyamines led to 
DNp73 degradation. Conversely, blocking Az1 expression by siRNA or with the natural 
inhibitor AZI abrogated stress-induced and c-Jun-mediated DNp73 degradation. As with 
all its substrates targeted for degradation, Az1 was found to be able to bind to DNp73 and 
cause the degradation of DNp73 in the absence of E1-ubiquitin activating enzyme 
activity, suggesting that DNp73 abundance is indeed regulated by Az1. Consistently, 
stress insults such as doxorubicin or UV were found to induce the expression of the 
processed Az1 product only in wild-type cells, but not in c-jun-/- cells. 
Az family consists of at least two other members, Az2 and Az3 (Mangold U, 2005). 
Since only Az1 has been shown to be able to degrade ODC, one would expect that 
DNp73 degradation upon stress is only dependent on Az1. Even though AZI can bind to 
all Az members, knock-down of only Az1 was enough to inhibit stress mediated 
degradation of DNp73, further supporting the unique role of Az1 in regulating DNp73 
levels. AZI has been shown to be up-regulated in many cancers (Nilsson J, 2000) and its 
tempting to speculate that it might be inhibiting degradation of DNp73, hence explaining 
the equally high expression of DNp73 in cancers. 
We observed that upon genotoxic stress, level of DNp73 poly-ubiquitination is down-
regulated (Figure 4 & 5). This decrease is not surprising since both Itch and FBXO45 
shown to ubiquitinate p73 at unstressed state (Rossi M et al., 2005; Peschiaroli A et al., 
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2009), are degraded upon stress, therefore not able to ubiquitinate DNp73. Interestingly, 
all other substrates of Az1 are also regulated by the ubiquitin-proteasome system. Hence, 
it would be interesting to understand the interplay between the ubiquitination status of 
DNp73 and its ability to be degraded by Az1. 
Both Az1 and its naturally occurring inhibitor, AZI are degraded by the ubiquitin-
proteasome system (Coffino P, 2001). Hence, inhibiting this pathway (by PYR-41), 
would lead to the up-regulation of both proteins. Since AZI has a high affinity for Az1, 
one would expect an inhibition of Az1 activity and binding to its substrates such as 
DNp73. However, we still show that degradation of DNp73 by Az1 can occur in 
ubiquitin deficient cells, indicating the existence of a mechanism to keep the levels of 
AZI low. It would be interesting to investigate the effect of stresses on AZI expression 
both at the RNA and protein level and whether c-Jun plays a role in such a regulation. 
Preliminary analysis indicates the presence of several AP-1/c-Jun binding sites in AZI 
promoter. Therefore one can hypothesize that under stress conditions, c-Jun binding to 
AZI promoter may repress its transcription, hence allowing newly synthesized Az1 to 
target their substrate such as DNp73. 
We also showed that Az1 could bind to DNp73, leading to its degradation. Az1 binding 
to its target ODC induces a conformational change that exposes a degradation motif, 
which is recognized by the proteasome (Coffino P, 2001). Where exactly does Az1 bind 
to DNp73 and whether a mechanism similar to that of ODC degradation is used by Az1 
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5.1.5 How does c-Jun induce antizyme 1 expression upon stress? 
The results presented here show that c-Jun induces the degradation of DNp73 probably 
by regulating the polyamine biosynthesis pathway in a transcription-dependent manner. 
ODC, the rate-limiting enzyme in this particular pathway does not appear to be the target 
of c-Jun in this situation, even though stress could induce odc expression in a c-Jun-
dependent manner. Moreover, genetic and chemical inhibition of ODC did not prevent 
the stress-mediated degradation of DNp73. However, a study has shown that inhibition of 
ODC by siRNA or DMFO does not completely abrogate the polyamines synthesis in the 
cells (Cowan MJ et al., 2006). Treatment with ODC siRNA decreased the levels of 
putrescine and spermidine levels by 30–70%, whereas its effect on spermine levels was 
negligible. Additionally, DMFO treatment decreased putrescine and spermidine levels by 
more that 90% and but spermine levels to only 50%. Since all polyamines are able to 
induce Az1 production (Coffino P, 2001), albeit to a varying degree, one can not 
completely rule out the role of ODC and that some levels of Az-1 were still present after 
ODC inhibition and enough to degrade DNp73 upon stress insults. It is noteworthy that a 
recent paper showed that spermine synthase is a not single but a complex of proteins 
(Zhou X et al., 2010) and one cannot rule out a role of c-Jun in regulating the other 
proteins in the complex. 
Furthermore, c-Jun might be regulating multiple target genes in the polyamine 
biosynthesis pathway or work as a transcriptional repressor of genes such polaymine 
oxidase (PAO) or spermidine spermine N'-acetyl transferase (SSAT), which breaks down 
polyamines in the cells (Coffino P, 2001). Indeed, preliminary promoter analysis of 
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various polyamine metabolic and catabolic genes indicated the presence of multiple 
putative AP-1/c-Jun binding sites. 
One other possible avenue via which c-Jun can induce Az1 expression upon stress is by 
regulating polyamine intake into cells. Besides being synthesized in cells, polyamines can 
be obtained from outside the cells (Coffino P, 2001). However, a polyamine transporter 
has yet to be discovered and it would be interesting to see if c-Jun could regulate the 
activity of the latter. 
Thus, the identity of the regulator of Az1 processing that is induced by c-Jun remains to 
be elucidated. Nonetheless, these data together establish that DNp73 can indeed be 
subjected to degradation by the non-classical Az pathway upon stress stimulation, in a c-
Jun-dependent manner. 
 
5.1.6 Differential stress degradation mechanism for between DNp73 and DNp63 
p63, the other member of the p53 family, also exists as two forms namely TAp63 and 
DNp63. Similar to DNp73, DNp63 level is also down-regulated upon genotoxic stresses 
but through different mechanisms (Li Y et al., 2009). It is proposed that under non-
stressed state, Stxbp4, a protein containing a WW-motif, prevents the degradation of 
DNp63 by Itch E3 ligase (which also contains a WW-motif and binds to the PY-motif 
found in both p73 and p63) and other E3 ligases. Upon stress, Stxbp4 is degraded, 
leading to the degradation of DNp63 via the proteasome. However, DNp63 degradation 
was not dependent on Itch during stress exposure but partially dependent on RACK1, a 
scaffold protein shown to bind to DNp63. RACK1 contains WD-40 repeats that are 
commonly used by proteins that target substrates for degradation through multi-subunit 
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E3 ligases. The authors speculate that the degradation of DNp63 by stress observed is by 
an unidentified E3 ligase associated with RACK1. Interestingly, RACK1 has also been 
shown to bind to p73 but did not affect its steady-state level (Ozaki T et al., 2003). 
Moreover, this interaction occurred via the C-terminal domain present only in α-forms of 
p73. Since both DNp73α and DNp73β are degraded upon genotoxic stress, one can 
expect this process to be independent of RACK1. The fact that stress-mediated 
degradation of DNp73 degradation is ubiquitin-independent further argue against a role 
of RACK1. Finally, since both TAp73 and DNp73 have the PY-motif, it would be 
interesting to investigate whether Stxbp4 has a role in regulating the levels of p73, under 
what conditions and how it affects the binding of NELD2, YAP and Itch, shown to 
associate with p73 at similar motif. DNp73 and DNp63 are highly homologous but yet 
have both overlapping and distinct functions. Expression of both proteins has been shown 
to inhibit the transcriptional activities and apoptotic pathways induced by p53, TAp63 
and TAp73 (DeYong MP and Ellisen LW, 2007). However, unlike DNp73, DNp63 is 
highly expressed in stratified epithelia and both knock-out mice have different 
phenotypes (Candi E at al., 2008). Therefore, one can hypothesize that these proteins 
have evolved to perform under different physiological settings, hence the need for 
distinct modes of regulation. 
 
5.1.7 Differential effect of antizyme1 on TAp73 and DNp73 
One important question that needs to be addressed is why does Az1 degrade DNp73 and 
not TAp73 (data not shown)? Antizyme binding to its substrate such as ODC is an 
intermediate step in the degradation process (Coffino P, 2001). Binding of Az1 prevents 
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the formation of an ODC homodimer resulting in the exposure of a segment on ODC, 
which is then recognized by the proteasome, thus leading to its destruction. Since the 
only difference between TAp73 and DNp73 is the N-terminal transactivation (TA) 
domain, one can assume that the TA domain plays a role in the distinct regulation of p73 
forms by Az1. 
One explanation might be the intra-molecular folding between the TA domain and C-
terminal part of p73, hence masking the ‘proteasome recognition signal’ that is exposed 
in DNp73. Intra-molecular folding has been shown to happen between the TA and the 
extreme C-terminal domains in TAp63α as a mechanism to suppress TAp63 
transcriptional activity (Serber Z et al., 2002). Another possible scenario is due to the 
binding of other proteins or specific post-translational modifications on the TA domain 
that can prevent its degradation. It is noteworthy that p73 levels can be regulated by 
neddylation pathway (Bernassola F et al., 2004). One study showed Nedd8 can only bind 
to the TA domain of p73, thereby illustrating a mechanism that is distinct for TAp73 and 
DNp73 (Watson IR et al., 2006). Therefore it would be interesting to assess whether this 
modification affects the binding of Az1 to p73. Moreover, both p300 and Mdm2 bind 
specifically to the TA domain of p73 (Zeng XY et al., 1999; 2000). Binding affinity of 
p300 to TAp73 was recently shown to increase upon phosphorylation of an amino acid 
residue at the TA domain (Burge S et al., 2009). Therefore one might hypothesize that 
upon stress treatment, phosphorylation events at the TA domain induces the recruitment 
of proteins like p300, which might contribute to its protection from Az-1, mediated 
degradation. Additionally, we have previously shown that the TA domain of p73 contains 
elements that regulate its steady-state independent of p73 transcriptional ability (Dulloo I 
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and Sabapathy K, 2005). All the above scenarios might indirectly affect the binding of 
Az1 to TAp73. Therefore carrying out binding assay between TAp73 and Az1 is critical 
to better understand the differential effect of Az1 on TAp73 and DNp73. 
Az1 has been shown to translocate to the nucleus during mouse development to induce 
the proteasomal degradation of ODC (Gritli-Linde A et al., 2001). Additionally, the 
ternary complex formed between Smad1-HsH3-Az1 was found to translocate to the 
nucleus in response to bone morphogenetic protein type 1 receptor activation for Smad1 
degradation (Lin Y et al., 2002). Antizyme-1 was also detected in the nucleus co-
localized with ODC after treatment of carcinoma cells with polyamines or polyamine 
analogs (Schipper RJ et al., 2004). Interestingly, p73 protein has been shown to have both 
nuclear localization and export signals and mutation of any of these signals leads to a 
more stable p73 protein (Inoue T et al., 2002). A recent study reported different 
intracellular compartmentalization of TAp73 and DNp73 in non-small cell lung cancer 
(Di Vinci A et al., 2009). Therefore one can hypothesize that cellular location of TAp73 
and DNp73, which might be different under stress conditions, can contribute to the 
distinct effect of Az1 on these p73 forms.  
 
5.1.8 Effect of Az1-mediated degradation of DNp73 in cancer 
5.1.8.1 On the dominant negative functions of DNp73 
Az1 has been shown to be a potent tumor-suppressor gene and expression of which can 
inhibit cellular growth and tumorigenesis (Feith DJ et al., 2001; Fong LY et al., 2003). It 
also targets several positive regulators of cellular proliferation, such as Smad1, cyclinD1 
and Aurora-A. Consistent with this is our data that has identified DNp73, which has anti-
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apoptotic properties, as yet another target degraded by Az1. Therefore, one could 
envisage that Az1 processing and activation upon genotoxic stress would lead to DNp73 
degradation, freeing the pro-apoptotic TAp73 protein as well as p53 from inhibitory 
effects of DNp73, leading to an appropriate stress response 
 
5.1.8.2 On the non-dominant negative functions of DNp73 
Over-expression of Az1 has been shown to lead to apoptosis and cell cycle arrest in a few 
systems (Murakami Y et al, 1994; Koike C et al., 1999; Iwata S et al., 1999). 
Degradation of oncogenic DNp73 might be one of the several pathways via which Az1 
exerts its tumor suppressor activities. Originally assumed to have no transactivation 
potential, DNp73 expression has now been shown to transcriptionally up-regulate the 
levels of many cancer-associated genes such as platelet-derived growth factor β-receptor 
(PDGFRB) and caspase 2S among others. Caspase 2S, is the anti-apoptotic isoform of 
caspase 2 gene preferentially expressed in brain and skeletal muscles and it inhibits cell 
death upon over-expression (Wang L et al., 1994). DNp73 binds to the promoter of 
caspase 2S and induces its expression that confers an increase resistance to cell death 
upon genotoxic stress in SHSYSY neuroblastoma cells (Toh WH et al., 2009). Equally, 
PDGFRB, known to play an important role in cellular proliferation, is activated by 
DNp73 and has been proposed to be causal to the high levels of PDGFRB seen in many 
cancers (Wetterskog D et al., 2009). Moreover, expression of DNp73 has been 
demonstrated to down-regulate the levels of the tumor suppressor PTEN at the RNA level 
and this effect was independent of the mechanism via which p53 is known to 
transcriptionally up-regulate PTEN expression (Vella V et al., 2009). Therefore, the 
 138
Chapter 5: Discussion 
 
down-regulation of oncogenic proteins and up-regulation of tumor suppressor by Az1 via 
modulating DNp73 levels could be another way via which cells respond to genotoxic 
insults.
 
5.1.9 Effect of Az-mediated degradation of DNp73 in development 
Az expression at the mRNA and protein levels was found to be regulated during mouse 
development (Gritli-Linde A et al., 2001), implying that Az and polyamines might have 
important functions during embryonic development. Similarly, DNp73 is involved in 
cellular developmental and differentiation processes (Huttinger-Kirchhof N et al., 2006; 
Danilova N et al., 2008). For example, levels of p73 are increased in neuroblastoma cells 
during retinoic-acid mediated differentiation (De Laurenzi V et al., 2000). Additionally, 
DNp73 can also negatively regulate nerve-growth factor-mediated neuronal 
differentiation through the trans-repression of TrkA (Zhang J and Chen X, 2007). The 
original p73 knock-out mice where both TAp73 and DNp73 were deleted showed severe 
defects in processes such as neurogenesis and this was attributed to the absence of 
DNp73 since it is the predominant form in the developing mouse brain (Yang A et al., 
2000). This observation was recently strengthened when TAp73-specific knock-out mice 
had much less severe developmental defects, confirming the predominant role of DNp73 
in developmental processes (Tomasini R et al., 2008). Hence, it is tempting to speculate 
that the relationship seen in this study between DNp73 and Az1 under genotoxic stress 
conditions might also have some relevance in embryonic development and differentiation 
processes. 
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Moreover, DNp73 has been shown to exert protective function in the brain under two 
circumstances. Firstly, withdrawal of nerve-growth factor, a process required for the 
development of mouse sympathetic neurons, induces p53-mediated cell death, and this 
can be inhibited by DNp73 expression (Lee AF et al., 2004). Secondly, a recent study 
provided evidence that DNp73 protects neurons against the hyper-phosphorylation of tau, 
a microtubule-associated protein, and neurofibrillary tangles which are linked to neuronal 
degeneration observed in diseases such as Alzheimer’s disease (Wetzel MK et al., 2008). 
Interestingly, a report has demonstrated that in yeast cells, Az1 frame-shifting process 
could be stimulated by [PSI+], the prion form of eukaryotic release factor 3 (eRF3) 
(Namy O et al., 2008). Thus, it is appealing to hypothesize that [PSI+] or maybe other 
prion-type proteins might have an effect on DNp73 expression in neuronal cells via Az1 
regulation. The above facts strongly suggest that the interaction of Az1 and DNp73 might 
be relevant in some type of neurological disorders. 
 
5.1.10 Why this specific mechanism for DNp73? 
One obvious question is why does DNp73 need to be regulated in such a distinct manner 
upon stress via the antizyme-mediated proteasomal degradation pathway and not the 
classical ubiquitin-proteasome system? In the context of tumorigenesis, one can speculate 
that DNp73 is a critical player in cancer onset, development and progression. Over-
expression of DNp73 appears to exert a dual effect in terms of its ability (1) to inhibit the 
function of the key tumor suppressors p53, TAp73 and TAp63 within the family (2) and 
to transactivate other tumor promoting genes as well as repressing tumor suppressing 
genes. Therefore, a tight control system is required to keep this oncogenic protein in 
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check.  Additionally, relying on the ubiquitin system might not be sufficient as alterations 
in E3 ubiquitin ligases which render them non-functional, is a frequent event in most 
cancers (Chen C et al., 2006; Confalonieri S et al., 2009). So far no mutations have been 
reported for Az1 protein. 
 
5.1.11 Clinical relevance of this knowledge 
Polyamines are critical for maintaining cellular growth and their metabolism has become 
an ideal therapeutic target in diseases such as cancer. Inhibiting key enzymes in the 
polyamine biosynthesis pathway alone are not very effective due to the compensatory 
mechanisms such as the polyamine uptake from external sources like the intestines 
(Coffino P, 2001). Therefore polyamine analogs, which are easily synthesized, highly 
water soluble and stable, can compete with the physiological polyamines and at the same 
time able to induce antizyme production are ideal therapeutic molecules (Casero RA Jr 
and Marton LJ, 2007). Several polyamine analogs have shown promising effect in 
different cancer cell lines such as breast and lung cancer (McCloskey DE et al., 1995; 
1996). Base on the data presented, one would expect that combination therapy of 
polyamine analogs together with chemotherapeutic drugs might be a very potent drug 
regimen in treating cancers, especially those known to over-express DNp73. Indeed, 
preliminary results have demonstrated promising outcome combining standard 
chemotherapy with polyamine analogs in several breast cancer and colon cancer cell lines 
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5.1.12 Perspectives 
Transgenic mice over-expressing a constitutively active mutant of MEK under 
keratinocyte specific promoter (K14-MEK mice) develops spontaneous skin tumor 
development within 5 weeks birth, even without the need of chemical initiation or 
promotion (Feith DJ et al, 2005; 2006). Crossing these mice with K5-Az and K6-Az mice 
significantly delayed tumor incidence compared to the K14-MEK mice alone, indicating 
that Az has indeed tumor suppressive effects (Feith DJ et al., 2006). To show the 
physiological relevance of this Az1-mediated degradation of DNp73, it would be ideal to 
generate DNp73 transgenic mice under similar promoters as all data indicate strong 
oncogenic properties of this form of p73. If similar to K14-MEK mice, these DNp73-
overexpressing transgenic mice develop spontaneous tumors or upon chemical initiation 
(UV irradiation or DMBA treatment), it would be interesting to cross them with the Az 
transgenic mice to analyze if the tumor burden is decreased, hence providing a very 
strong physiological evidence of Az1 effect on DNp73. 
This study has clearly shown that c-Jun is acting upstream of Az1 production upon 
genotoxic stress, implying a possible role of c-Jun in the polyamine biosynthesis 
pathway. However, in c-Jun knock-out cells, Az1 expression could be induced by 
exogenous putrescine, indicating that frameshifting machinery itself was functional and 
that indeed c-Jun was upstream of the polyamine biosynthesis pathway.  To further 
solidify this hypothesis, the levels of the different polyamines in wild-type and c-Jun 
knock-out cells after stress treatments need to be measured.  
It is noteworthy that known Az1 targets namely Smad1, Cyclin D1 and Aurora-A, are cell 
cycle regulators. Az1-mediated degradation of cyclin D1 was proposed as a method to 
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inhibit cell proliferation with G1 arrest following Az1 up-regulation (Newman RM et al., 
2004). However, whether the regulation of all the substrates by Az1 is cell-cycle 
dependent has yet to be clearly shown. TAp73 and p53 are known to regulate cell cycle 
via the induction of cell-cycle inhibitor p21, which can be counteracted by the over-
expression of dominant negative DNp73 (Melino G et al., 2002). Therefore, it would be 
interesting to investigate if Az1 regulate the levels of dominant-negative DNp73 in this 
physiological context. 
Centrosome defects and chromosomal instability are established markers of cancer 
(Fukasawa K, 2005). Az1 and AZI have been shown to concentrate at centrosomes and 
the depletion of antizyme in various tumors cell lines and primary cells led to centrosome 
over-duplication whereas over-expression of antizyme reduces numerical centrosome 
abnormalities (Mangold U et al., 2008). Interestingly, stable over-expression of DNp73 
can induce genomic instability of tumors via the formation of tetraploid cells (Marrazzo 
E et al., 2009). Hence, it would be interesting to investigate the role of AZ1-mediated 










Chapter 5: Discussion 
 
5.2 Overview 
Non-genotoxic stress such as hypoxia plays an important role in tumor growth and 
survival. Unlike p53, the regulation of p73 and subsequent physiological effect by non-
genotoxic stresses is lacking. Both TAp73 and DNp73 are often over-expressed in many 
solid tumors, which are hypoxic. Therefore we decided to investigate if hypoxic stress 
could regulate the levels of p73. The data presented there show for the first time that 
hypoxia, non-genotoxic stress, can up-regulate the levels of both TAp73 and DNp73. 
Similar to HIF1α, p73 is modified by an unknown prolyl-4-hydroxylase and leading to its 
degradation at normoxia. Upon hypoxia, p73 is regulated by the AMPK signaling, 
leading to its stabilization. And one possible outcome of this process is to sustain the 
autophagic process, hence playing a pro-survival role in cancer.  
5.2.1 Stabilization of p73 by hypoxia 
Treatment of HCT116 cells with hypoxic stress led to the up-regulation of TAp73, 
paralleled with an increase in p53 levels. HCT116 cell line lacks a functional MLH1, a 
mismatch repair gene and it has been shown that treatment with DNA-damaging insults 
such as cisplatin does not lead to TAp73 stabilization as seen in other cell lines (Gong JG 
et al., 1999). Interestingly, hypoxia was able to increase TAp73 level in HCT116 cells, 
indicating that different signaling pathways are triggered by genotoxic and non-genotoxic 
stresses to up-regulate p73 level and probably trigger a distinct gene expression pattern. 
Activation of TAp73 by upon genotoxic stress via the MLH1-c-Abl pathway is needed to 
induce its pro-apoptotic functions (Gong JG et al., 1999), suggesting that stabilization of 
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TAp73 by hypoxic stress, which does not immediately cause DNA damage, might lead to 
a non-apoptotic response. 
Unlike canonical targets of HIF1α, vegf and glut-1, no change in the amount of TAp73 
transcript was observed, indicating that p73 is unlikely to be transcriptionally regulated 
by HIF1α or any other factors upon hypoxia and that the up-regulation of TAp73 
occurred at the protein level. Indeed, stabilization of TAp73 and DNp73 under the control 
of a constitutive cytomegalovirus (CMV) or inducible (Tetracycline-ON) promoter by 
hypoxic stress confirmed the post-translational regulation of p73, similar to HIF1α. 
 
5.2.2 Regulation of p73 by hypoxia does not involve the VHL E3 ubiquitin ligase 
Time-course analysis showed that both TAp73 and DNp73 levels increased quickly upon 
hypoxic stress and were similarly down-regulated upon re-oxygenation. This kinetics of 
protein turnover indicated that p73 was likely to be regulated by the efficient fast-acting 
ubiquitin-proteasome system, analogous to HIF1α regulation under different O2 tension 
(Kaelin WG, 2008). Indeed we observed that hypoxia decreased the amount of p73 
polyubiquitinated species but however, unlike HIF1α, this process did not involve the 
VHL E3 ligase. VHL, an SCF-type E3 ubiquitin ligase, has been shown to keep HIF1α 
levels low under normoxic conditions and upon hypoxia this interaction is inhibited, 
hence leading to the stabilization of HIF1α (Kaelin WG, 2008). The non-involvement of 
VHL and FBXO45, a recently identified SCF-type E3 ubiquitin ligase shown to regulate 
p73 levels (Peschiaroli A et al., 2009), in O2-mediated regulation of p73 was confirmed 
in a cell line defective in the neddylation, a protein modification needed on cullins for 
efficient ubiquitination process by SCF-type E3 ligase complexes (Rabut G and Peter M, 
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2008). These indicate that a non SCF-type E3 ligase might be responsible for regulating 
p73 levels under different O2 tension.  
The non-involvement of VHL in O2–dependent regulation of a protein has been 
previously shown in the case of ATF4 (Ameri K et al., 2004; Koditz J et al., 2007). ATF4 
was regulated under hypoxic conditions by PHD3 and the role of SCFβTRCP ubiquitin 
ligase has been inferred as the ligase keeping ATF4 levels low at normoxia. However, 
being an SCF-type E3 ligase, one can assume that SCFβTRCP ubiquitin ligase, just like 
VHL and FBXO45, is unlikely to be involved in the O2-mediated regulation of p73. 
Several other E3 ligases have been associated with p73 such as Mdm2, NEDL2 and Itch 
(Balint E et al., 1999; Miyazaki K et al., 2003; Rossi M et al., 2005). Itch E3 ubiquitin 
ligase has been shown to induce the degradation of p73 under non-stressed conditions 
(Rossi M et al., 2005) Upon genotoxic stress, Itch is degraded, leading to the stabilization 
of TAp73. However, silencing of Itch did not affect TAp73 regulation by different O2 
tension, indicating that Itch probably regulates p73 level under genotoxic conditions only. 
Indeed, exposure to hypoxic stress up to 48hrs did not lead to the down-regulation of Itch 
level (data not shown). Both Mdm2 and NEDL2 do not degrade p73 and hence they are 
unlikely to be involved in its regulation under hypoxic conditions. 
Interestingly, expression of VHL E3 ligase down-regulated the levels of both TAp73 and 
DNp73. Besides HIF1α regulation under different O2 tension, VHL has also been shown 
to be involved in microtubule dynamics, cell proliferation, neuronal apoptosis and others 
(Frew IJ and Krek W, 2007). Mutations in VHL tumor suppressor gene have been 
associated with development of cancer such as tumors in the kidney and central nervous 
system among others (Kim WY and Kaelin WG, 2004). These mutations very often 
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either affect the binding of VHL to its substrates or its E3 ubiquitin ligase activity. 
Therefore, it would be interesting to determine whether cancers with VHL mutations 
have high levels of p73 and does VHL-mediated regulation of p73 has any role in those 
physiological settings. 
The observed decrease in ubiquitination and subsequent stabilization of TAp73 upon 
hypoxia could also be due to the activation of a deubiquitinating enzyme (DUB). DUBs 
are enzymes that cleave off polyubiquitin chains bound to substrate proteins and inhibit 
their proteasomal degradation, hence leading to the stabilization of the protein 
(Komander D et al., 2009). Indeed, expression of a VHL-interacting deubiquitinating 
enzyme, USP20, has been shown to counter the VHL-mediated ubiquitination of HIF1α 
under normoxic conditions leading to its up-regulation (Li Z et al., 2005). However, since 
VHL is not involved in O2-mediated regulation of p73, USP20 is unlikely to be a 
candidate DUB. So far, no other DUB has been reported to be involved in hypoxia. 
 
5.2.3 Role of prolyl-4-hydroxylases on p73 
Prolyl-4-hydroxylases (PHDs) are oxygen sensors and they have been shown to 
hydroxylate HIF1α at two specific proline residues at normoxia, leading to its recognition 
by VHL E3 ligase and subsequent degradation (Schofield CJ and Ratcliffe PJ, 2004). We 
found that hypoxia-mediated stabilization of p73 required a region containing a motif 
highly similar to those recognized by PHDs. Interestingly, mutation of the proline residue 
to alanine in the putative motif led to the stabilization of TAp73 at normoxia and 
abrogated its oxygen-mediated regulation, indicating that p73 may be regulated by a 
prolyl-4-hydroxylase at this sequence motif. 
 147
Chapter 5: Discussion 
 
It is noteworthy that the putative motif on p73 differs from the canonical motif at the 
alanine residue located just before the proline residue that usually gets hydroxylated. 
However, it has been shown that mutations can be tolerated at the -5, -2, and -1 positions 
(relative to proline) of the LXXLAP motif (Huang J et al., 2002), indicating that it is 
likely to be a target site for PHDs. This minor difference in the motif sequence might also 
account of the inability of VHL E3 ligase to recognize and regulate p73 levels. 
Conversely, the absence of a rigid consensus sequence for hydroxylation by PHDs 
implies any of the other 7 proline residues found within the region might also behave as a 
hydroxylacceptor. Indeed, ATF4 is regulated by PHD3 under hypoxia in a VHL-
independent manner (Ameri K et al., 2004; Koditz J et al., 2007). It was shown that 
ATF4 contains an oxygen-dependent degradation domain (ODD) that is required for its 
oxygen-mediated regulation and only mutation of all the prolines within that domain led 
to ATF4 stabilization at normoxia. However, it is noteworthy that no LXXLAP motif was 
detected within ATF4 ODD domain and directly hydroxylation of any of those pralines 
by PHD3 has yet to be shown. Additionally, alignment of the amino sequences of p73 to 
p53 and p63 showed that this putative motif was not present in either p53 or p63, 
indicating a probable unique regulation mechanism of p73 under hypoxic stress. 
Surprisingly, expression of all three PHDs known to regulate protein with this type of 
motif did not lead to the degradation of p73. Transient over-expression of these PHDs has 
been shown to regulate endogenous HIF1α levels at varying extent (Huang J et al., 
2002). Therefore, one can speculate that some unknown prolyl-4-hyroxylase might be 
modulating p73 levels under hypoxia and the presence of the valine instead of alanine at 
position –1 might be responsible for this distinction. This was further supported by the 
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fact that DMOG, a prolyl-4-hydroxylase inhibitor, could inhibit the oxygen-mediated 
regulation of p73. To completely exclude the role of the three PHDs tested and any 
unspecific effect of the chemical inhibitor DMOG, we need to silence the expression of 
the PHDs and assess its effect on the O2-mediated regulation of p73 in those cells. 
 
5.2.4 Role of kinases in regulating p73 upon hypoxia 
JNK1/2 and ERK1/2 signaling pathways are activated upon hypoxic stress (Garrington 
TP and Johnson GL, 1999; Jin N et al., 2000). JNKs phosphorylate p73 upon cisplatin 
treatment, leading to its stabilization (Jones EV et al., 2007) and inhibition of ERK1/2 
signaling has been shown to down-regulate the levels of p73 (Fernandez-Garcia B et al., 
2007). However, chemical inhibition of both signaling pathways did not abrogate the 
oxygen-mediated regulation of p73, indicating that JNKs and ERK1/2 regulate p73 levels 
under other physiological conditions and hence probably dictating the appropriate p73-
mediate response. It is noteworthy that activation of individual MAPK kinases by 
hypoxic stress can be cell-type dependent (Garrington TP and Johnson GL, 1999), 
therefore one can not completely rule out their involvement in p73 regulation by hypoxia 
in other cell lines. 
The AMP-activated protein kinase (AMPK) signaling pathway acts as an energy sensor 
and is sensitive to the cellular AMP: ATP ratio (Steinberg GR and Kemp BE, 2009). 
AMPK is a heterotrimeric serine/threonine kinase consisting of a catalytic a subunit (α1 
or α2) and non-catalytic, regulatory β and γ subunits, all of which are required for full 
kinase activity (Sanz P, 2008). AMPK is activated by metabolic stresses that inhibit ATP 
production such as glucose deprivation and hypoxia, which triggers catabolic pathways 
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that generate ATP, while switching off ATP-consuming, anabolic pathways (Steinberg 
GR and Kemp BE, 2009). Once activated, AMPK phosphorylates several target proteins, 
which are mostly cytoplasmic enzymes involved in glucose and lipid metabolism as well 
as regulating gene expression via transcription factors such as HIF1α and p53 (Leclerc I 
et al., 2002). 
Our data show that both chemical and genetic inhibition of AMPK abrogated the 
stabilization of p73 upon hypoxia, indicating that AMPK signaling pathway triggered by 
hypoxic stress can regulate p73 levels. Interestingly, a recent paper has reported that 
AMPKα binds to the extreme C-terminal of p73α but did not have any significant effect 
on its steady-state (Lee YG et al., 2009). p73α association with AMPKα led to a 
decrease in its transcriptional activity on various p53-responsive promoters such as p21, 
independent of AMPKα kinase activity. The effect of AMPK in our study is unlikely to 
be via a similar mechanism as TAp73β, lacking the extreme C-terminal domain proposed 
to bind to AMPKα, is up-regulated by hypoxia and it appears to be dependent on AMPK 
kinase activity. The authors also showed that AMPKα repressive interaction with p73α 
mediates cell survival in response to DNA damaging agents such as cisplatin (Lee YG et 
al., 2009), indicating that AMPK signaling pathway might regulate p73 in distinct 
manner, depending on the type of stress stimuli. 
The unexpected observation that AMPK inhibitor Compound C induced the steady-state 
levels of p73 at normoxia, alluded that perhaps AMPK has a repressive effect on p73 
under non-stressed conditions. However, no significant difference in p73 levels was 
observed in cells where the catalytic subunits AMPKα1 and AMPKα2 were genetically 
silenced. It has been reported that Compound C has unspecific effect on various other 
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kinases (Bain J et al., 2007; Emerling BM et al., 2007), indicating that the increase in p73 
levels at normoxia might be due to the inhibition of other signaling pathways that 
regulate p73.  
It was recently shown that in response to AICAR, an AMPK activator, or under low 
glucose conditions, AMPK activation induces the phosphorylation of human p53 on 
serine15 leading to cell-cycle arrest (Imamura K et al., 2001; Jones RG et al., 2005). 
However, the AMPK phosphorylation site in p53 is not conserved in p73. Therefore, 
whether AMPK effect on p73 during hypoxic stress is via direct phosphorylation or an 
indirect mechanism still remains to be elucidated.  
 
5.2.5 Hypoxia induction of p73 as a survival mechanism? 
Besides regulating normal glycolytic and oxidative metabolism upon metabolic stresses, 
activation of AMPK has been shown to also trigger autophagy as another method to 
maintain cellular energy balance (Meijer AJ and Codogno P, 2007). Autophagy is 
stimulated in tumor cells when present in a hypoxic environment to promote tumor cell 
survival (Degenhardt K, et al., 2006). Moreover, it has been shown that AMPK is 
induced by low O2 conditions and glucose deprivation conditions found in solid tumor 
microenvironments (Laderoute KR et al., 2006). Recently, a report has illustrated that 
hypoxia can trigger the autophagic pathway in several human cancer cell lines via the 
activation of AMPK, independent of HIF1α (Papandreou I et al., 2008). Since p73 has 
been associated with the induction of autophagy (Crighton D et al., 2007; Rosenbluth JM 
et al., 2008), we therefore proceeded to investigate whether p73 is involved in hypoxia-
mediated autophagy. Indeed, autophagy was observed in both HCT116 colon cancer cell 
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line as well as in MEFs in response to low oxygen. However, the level and duration was 
less pronounced and decreased significantly by 24hrs in p73-/- MEFs compared to wild-
type MEFs as seen by less LC3-II, paralleling a down-regulation of bnip3. 
BNIP3, a BH3-only pro-apoptotic protein, is induced upon hypoxia and has been shown 
to contribute to autophagic-cell death in various studies (Tracy K et al., 2007; Azad MB 
et al., 2007). However, BNIP3 has also been demonstrated to work as a pro-survival 
protein in hypoxia-induced autophagy (Pouyssegur J et al., 2006). Upon hypoxia, 
mitochondrial autophagy (mitophagy) is triggered by BNIP3 to remove damaged 
mitochondria and thus preventing the accumulation of toxic reactive oxygen species 
(Zhang H et al., 2008). Deletion of BNIP3 has also been shown to suppress autophagy 
and increase cell death in response to hypoxia (Mazure NM and Pouyssegur J, 2009), 
indicating that BNIP3 can work as a pro-survival protein. 
Therefore, the down-regulation of bnip3 observed in p73-/- MEFs (which lacks both 
TAp73 and DNp73) upon hypoxia can be interpreted as a marker for decrease cell 
viability and that p73 may be functioning as a pro-survival protein under hypoxic 
conditions. Such a role is not implausible, as we have previously shown that both TAp73, 
known to have the ability to support cell survival, and oncogenic DNp73, are both up-
regulated upon hypoxia. Additionally, the autophagy has been demonstrated in many 
solid tumors (Liang J et al., 2007) and hence it is advantageous for tumor cells to 
maintain high levels of TAp73 and DNp73, the main characteristic associated with p73 in 
cancer. Therefore, the absence of p73 means less ability to survive and proliferate for 
tumors cells. Further supporting this hypothesis is a recent study has reported that over-
expression of TAp73 induced autophagy in cancer cells and interestingly, unlike p53, did 
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not lead to cell death (Crighton D et al., 2007). Moreover, hypoxia-induced cell death has 
been shown to be dependent via p53 transcriptional activation of Fas/CD95 in HCT116 
colon cancer cell lines (Liu T et al., 2007). Therefore it is of interest to assess if p73-/- 
cells are more prone to autophagic cell death compared to wild type cells upon hypoxia.   
It was worth mentioning that the role of BNIP3 in autophagy has yet to be clearly 
elucidated. Many studies have shown that BNIP3 function as either a pro-apoptotic or a 
pro-survival factors upon hypoxia, can be dependent on cell types, time and percentage of 
oxygen and if in combination with factors like high glucose medium.  
One study has shown that p73 could induce autophagy-related genes upon serum-
starvation (Rosenbluth JM et al., 2008). And this process is regulated by the mammalian 
target of rapamycin (mTOR) pathway and inhibition of mTOR signaling led to the 
stabilization of p73. Additionally, it was shown that p73 could bind to the promoter 
sequences of several autophagy-related genes such as atg5 and atg7 (Rosenbluth JM and 
Pietenpol JA, 2009). AMPK has been shown to inhibit the mTOR signaling upon hypoxia 
(Meijer AJ and Dubbelhuis PF, 2004). Therefore, it would be interesting to investigate 
whether (1) the hypoxia-mediated up-regulation of p73 is due to the mTOR pathway 
inhibition by AMPK (2) p73 up-regulation upon hypoxia has any direct effect on the 
expression of atg5 and atg.  
One important question that also needs to be addressed is what effect does the 
simultaneous induction of TAp73 and DNp73 upon hypoxia has on apoptosis. p73-/- 
MEFs used are deleted for both TAp73 and DNp73 and the overall effect appears to be a 
decrease in cellular survival potential. Since p53 is also induced by hypoxia to trigger 
apoptosis, one can speculate that the up-regulation of DNp73 would implicate an 
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inhibition of p53 apoptotic potential besides triggering the appropriate oncogenic 
response. On the other hand, the simultaneous up-regulation of TAp73 might be causal 
for the induction of survival signals both via direct transcriptional activation or acting as 
a co-factor.  It would be desirable to investigate the individual role of TAp73 and DNp73 




p53 activation by AMPK has been shown to promote cell survival and proliferation in 
response to glucose starvation, which are distinct from p53 activation and subsequent cell 
cycle arrest or apoptosis in response to DNA damage (Jones RG et al., 2005). Therefore, 
one can speculate that AMPK-mediated stabilization of p73 upon hypoxia might be part 
of a survival mechanism for the cells to adapt to this unfavorable condition. Hypoxia 
significantly depletes ATP in the cells and activation of AMPK can stimulate ATP 
generation by increasing both glucose absorption and the rate of glycolysis to compensate 
for the lack of cellular energy (Steinberg GR and Kemp BE, 2009). Interestingly, GLX2, 
a gene encoding glyoxalase II enzyme, was reported to be up-regulated by p73 (Xu Y and 
Chen X, 2006). GLX2 is part of the glyoxalase system which main function if to detoxify 
the potent cytotoxic methylglyoxal, a by-product of glycolysis (Thornalley PJ, 2003). 
Over-expression GLX2 was shown to inhibit the apoptotic response of a cell to 
methylglyoxal. Therefore, it is tempting to speculate that one effect of AMPK regulation 
of p73 upon hypoxia is p73 activation of GLX2 to remove cytotoxic methylglyoxal, 
hence fulfilling its pro-survival functions.  
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Another pathway that is triggered by hypoxia is the unfolded protein response (UPR) via 
ER stress (Wouters BG and Koritzinsky M, 2008). UPR allows the elimination of 
misfolded proteins by the endoplasmic reticulum (ER) to prevent the accumulation of 
toxic protein aggregates, hence playing a protective role in response to hypoxia. 
However, UPR can also trigger cell death through regulation of apoptotic pathways (Ma 
Y and Hendershot LM, 2004). Expression of p73 has been previously shown to up-
regulate Scotin and CHOP levels, two ER-associated protein, leading to apoptosis 
(Terrinoni A et al., 2004). It is noteworthy that the UPR occurs mainly under drastic 
hypoxia (<0.01% O ), which is not physiologically representative of the oxygen 
concentration in most tumors. Therefore it would be worthwhile to investigate if p73 
plays any role in UPR upon hypoxia and whether p73 can differentially activate UPR, 
either for cell survival or contributing to cell death in extreme hypoxic conditions when 
survival can not be sustained.   
2
The fact that hypoxia up-regulates both transactivation proficient TAp73 and 
‘transactivation defective’ DNp73 is surprising but exciting, since many reports over the 
past few years have showed that DNp73 does have transcriptional activity and can 
activate a sub-set of genes on its own. To get a better understanding of the physiological 
significance of the stabilization of TAp73 and DNp73 by hypoxia, microarray studies 
using the newly generated TAp73-specific and DNp73-specific knock-out mice to see 
how the transcription profiles differ will be very informative. 
The perspective that hypoxic stress up-regulates p73 to trigger various survival signals 
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6. Conclusion 
This PhD study has contributed two novelties to the body of knowledge about the 
regulation and function of p73. In the first part, we have elucidated the long-standing 
question of how oncogenic dominant negative DNp73 is down-regulated in response to 
genotoxic stresses such as chemotherapeutic drugs. The relatively unknown antizyme-
polyamines degradation pathway plays a key role in this particular regulation of DNp73. 
This discovery will definitely have a wide impact in both the p73 and polyamines fields 
of research. The complete mechanism of how this degradation process takes place has yet 
to be elucidated but the data shown here strongly point to the relevance of polyamines in 
regulating p73 expression. With the fact that many cancers often over-express DNp73 
and the advent of polyamine analogs as therapeutic molecules, one can expect that this 
study might provide a baseline for future combinatorial drug regimen in the treatment of 
cancer. 
In the second part of this study, we have demonstrated that p73 can be equally regulated 
by non-genotoxic stress namely hypoxia. Until now, no studies have explored the effect 
of hypoxic stress on p73 levels in cancer. Though still premature, the data shown here 
indicate that p73 up-regulation might have a supportive role in tumorigenesis, a concept 
that has emerged over the past few years, via the modulation of autophagy. The 
involvement of AMPK signaling, a cell survival pathway, in the hypoxia-mediated 
stabilization of p73 together with the recurring fact that p73 proteins are not mutated but 
highly over-expressed in many tumors, strongly argue for such a role. 
This study has further shown the diversity of regulatory mechanisms that exist in cells to 
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